10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2019

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                       to                     

Commission file number: 000–26495

CYREN LTD.

(Exact name of Registrant as specified in its charter)

Israel	Not applicable
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

10 Ha-Menofim St., 5th Floor
Herzliya, Israel	4672561
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code 011–972–9–863–6888

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒  No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒  No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-Accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ☐  No ☒

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Ordinary Shares, par value ILS 0.15 per share	CYRN	Nasdaq Capital Market

Indicate the number of shares outstanding of each issuer’s classes of common stock, as of the latest practicable date: 59,319,391 ordinary shares as of November 7, 2019.

Table of Contents

		Page
PART I – FINANCIAL INFORMATION
Item 1.	Financial Statements
	Consolidated Balance Sheets as of September 30, 2019 (unaudited) and December 31, 2018	2
	Consolidated Statements of Operations (unaudited) for the three and nine months ended September 30, 2019 and 2018	4
	Consolidated Statements of Comprehensive Loss (unaudited) for the three and nine months ended September 30, 2019 and 2018	5
	Consolidated Statement of Changes in Shareholders’ Equity (unaudited) for the three and nine months ended September 30, 2019 and 2018	6
	Consolidated Statements of Cash Flows (unaudited) for the nine months ended September 30, 2019 and 2018	8
	Notes to Consolidated Financial Statements (unaudited)	10
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	22
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	30
Item 4.	Controls and Procedures	32
PART II – OTHER INFORMATION
Item 6.	Exhibits	33
SIGNATURES		34

i

CYREN LTD.

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF September 30, 2019

($USD in thousands, except share and per share amounts)

(Unaudited)

	Page
PART I – FINANCIAL INFORMATION
ITEM 1. Financial Statements (Unaudited)	2
Condensed Consolidated Balance Sheets	2
Condensed Consolidated Statements of Operations	4
Condensed Consolidated Statements of Comprehensive Loss	5
Condensed Consolidated Statement of Changes in Shareholders’ Equity	6
Condensed Consolidated Statements of Cash Flows	8
Notes to Condensed Consolidated Financial Statements	10

-1-

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS.

CYREN LTD.

CONDENSED CONSOLIDATED BALANCE SHEETS

($USD in thousands, except share and per share amounts)

(Unaudited)

	September 30,		December 31,
	2019		2018
	Unaudited
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	9,546	$	17,571
Trade receivables (net of allowances for doubtful accounts of $21 and $20, respectively)		3,499		3,658
Deferred commissions		930		887
Prepaid expenses and other receivables ($- and $6 attributable to related parties)		1,329		778
Total current assets		15,304		22,894
LONG-TERM ASSETS:
Long-term deferred commissions		1,646		1,880
Long-term lease deposits		782		821
Operating lease right-of-use assets		8,974		-
Severance pay fund		610		503
Property and equipment, net		4,437		4,608
Intangible assets, net		8,667		8,802
Goodwill		19,904		20,519
Total long-term assets		45,020		37,133
Total assets	$	60,324	$	60,027

The accompanying notes are an integral part of the interim consolidated financial statements.

-2-

CYREN LTD.

CONDENSED CONSOLIDATED BALANCE SHEETS

($USD in thousands, except share and per share amounts)

(Unaudited)

	September 30,			December 31,
	2019			2018
	Unaudited
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES:
Trade payables	$	1,402		$	1,668
Employees and payroll accruals		3,690			3,959
Accrued expenses and other liabilities		1,421			910
Operating lease liabilities		1,298			-
Earn-out consideration		-			2,926
Deferred revenues		9,270			5,773
Total current liabilities		17,081			15,236
LONG-TERM LIABILITIES:
Deferred revenues		2,944			503
Convertible notes		10,000			10,000
Long-term operating lease liabilities		7,993			-
Deferred tax liability		912			1,130
Accrued severance pay		778			598
Other liabilities		337			700
Total long-term liabilities		22,964			12,931
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY:
Ordinary shares nominal value ILS 0.15 par value -
Authorized: 110,000,000 shares at September 30, 2019 (Unaudited) and 75,353,340 shares at December 31, 2018; Issued: 54,683,807 and 54,405,881 shares at September 30, 2019 (Unaudited) and December 31, 2018, respectively; Outstanding: 54,683,807 and 54,057,208 shares at September 30, 2019 (Unaudited) and December 31, 2018, respectively		2,099			2,097
Additional paid-in capital		246,554			245,570
Treasury shares at cost – 0 and 348,673 Ordinary shares at September 30, 2019 (Unaudited) and December 31, 2018, respectively		-			(998	)
Accumulated other comprehensive loss		(2,384	)		(1,666	)
Accumulated deficit		(225,990	)		(213,143	)
Total shareholders’ equity		20,279			31,860
Total liabilities and shareholders’ equity	$	60,324		$	60,027

The accompanying notes are an integral part of the interim consolidated financial statements.

-3-

CYREN LTD.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

($USD in thousands, except share and per share amounts)

(Unaudited)

	Three months ended September 30,						Nine months ended September 30,
	2019			2018			2019			2018
	Unaudited						Unaudited
Revenues	$	9,496		$	9,562		$	28,862		$	26,388
Cost of revenues		3,712			3,670			11,501			10,684
Gross profit		5,784			5,892			17,361			15,704
Operating expenses:
Research and development, net (1)		3,516			4,336			11,990			11,355
Sales and marketing		3,027			3,931			10,473			12,133
General and administrative		2,484			2,166			7,314			6,151
Total operating expenses		9,027			10,433			29,777			29,639
Operating loss		(3,243	)		(4,541	)		(12,416	)		(13,935	)
Other income (expense), net		(3	)		-			262			(17	)
Financial income (expense), net		(321	)		7			(642	)		(91	)
Loss before taxes on income		(3,567	)		(4,534	)		(12,796	)		(14,043	)
Tax benefit		37			107			117			201
Loss	$	(3,530	)	$	(4,427	)	$	(12,679	)	$	(13,842	)
Basic and diluted loss per share	$	(0.06	)	$	(0.08	)	$	(0.23	)	$	(0.26	)
Weighted average number of shares used in computing basic and diluted loss per share		54,554			53,679			54,389			53,503

⁽¹⁾ Transactions with related parties are included in the line item above (refer to Footnote 7, Related Parties, of the Notes to Consolidated Financial Statements for additional information).

The accompanying notes are an integral part of the interim consolidated financial statements.

-4-

CYREN LTD.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

($USD in thousands, except share and per share amounts)

(Unaudited)

	Three months ended September 30,						Nine months ended September 30,
	2019			2018			2019			2018
	Unaudited						Unaudited
Loss	$	(3,530	)	$	(4,427	)	$	(12,679	)	$	(13,842	)
Other comprehensive income (loss):
Foreign currency translation adjustments		(622	)		16			(718	)		(291	)
Comprehensive loss	$	(4,152	)	$	(4,411	)	$	(13,397	)	$	(14,133	)

The accompanying notes are an integral part of the interim consolidated financial statements.

-5-

CYREN LTD.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY 

($USD in thousands, except share and per share amounts)

(Unaudited)

	Three months ending September 30, 2018
	Number of outstanding ordinary shares		Share capital		Additional paid-in capital			Treasury shares			Accumulated other comprehensive income (loss) (*)			Accumulated deficit			Total shareholders’ equity
Balance as of June 30, 2018 (Unaudited)		53,524,247	$	2,097	$	245,176		$	(2,762	)	$	(1,502	)	$	(202,854	)	$	40,155
Issuance of treasury shares upon exercise of options and vesting of restricted share units		478,491		-		(345	)		1,608			-			(279	)		984
Stock-based compensation related to employees, directors and consultants		-		-		358			-			-			-			358
Other comprehensive loss		-		-		-			-			16			-			16
Cumulative effect of accounting change		-		-		-			-			-			-			-
Loss		-		-		-			-			-			(4,427	)		(4,427	)
Balance as of September 30, 2018 (Unaudited)		54,002,738	$	2,097	$	245,189		$	(1,154	)	$	(1,486	)	$	(207,560	)	$	37,086

	Nine months ending September 30, 2018
	Number of outstanding ordinary shares		Share capital		Additional paid-in capital			Treasury shares			Accumulated other comprehensive income (loss) (*)			Accumulated deficit			Total shareholders’ equity
Balance as of December 31, 2017		53,375,854	$	2,097	$	244,609		$	(3,312	)	$	(1,195	)	$	(195,098	)	$	47,101
Issuance of treasury shares upon exercise of options and vesting of restricted share units		626,884		-		(451	)		2,158			-			(431	)		1,276
Stock-based compensation related to employees, directors and consultants		-		-		1,031			-			-			-			1,031
Other comprehensive loss		-		-		-			-			(291	)		-			(291	)
Cumulative effect of accounting change		-		-		-			-			-			1,811			1,811
Loss		-		-		-			-			-			(13,842	)		(13,842	)
Balance as of September 30, 2018 (Unaudited)		54,002,738	$	2,097	$	245,189		$	(1,154	)	$	(1,486	)	$	(207,560	)	$	37,086

-6-

CYREN LTD.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY – (Continued)

($USD in thousands, except share and per share amounts)

(Unaudited)

	Three months ending September 30, 2019
	Number of outstanding ordinary shares		Share capital		Additional paid-in capital		Treasury shares		Accumulated other comprehensive income (loss) (*)			Accumulated deficit			Total shareholders’ equity
Balance as of June 30, 2019		54,501,307	$	2,098	$	245,905	$	-	$	(1,762	)	$	(222,460	)	$	23,781
Issuance of treasury shares upon exercise of options and vesting of restricted share units		-		-		-		-		-			-			-
Issuance of ordinary shares upon exercise of options		182,500		1		230		-		-			-			231
Payment of interest in shares		-		-		-		-		-			-			-
Stock-based compensation related to employees, directors and consultants		-		-		419		-		-			-			419
Other comprehensive loss		-		-		-		-		(622	)		-			(622	)
Loss		-		-		-		-		-			(3,530	)		(3,530	)
Balance as of September 30, 2019 (Unaudited)		54,683,807	$	2,099	$	246,554	$	-	$	(2,384	)	$	(225,990	)	$	20,279

	Nine months ending September 30, 2019
	Number of outstanding ordinary shares		Share capital		Additional paid-in capital			Treasury shares			Accumulated other comprehensive income (loss) (*)			Accumulated deficit			Total shareholders’ equity
Balance as of December 31, 2018		54,057,208	$	2,097	$	245,570		$	(998	)	$	(1,666	)	$	(213,143	)	$	31,860
Issuance of treasury shares upon exercise of options and vesting of restricted share units		348,673		-		(403	)		998			-			(168	)		427
Issuance of ordinary shares upon exercise of options		241,976		1		315			-			-			-			316
Payment of interest in shares		35,950		1		70			-			-			-			71
Stock-based compensation related to employees, directors and consultants		-		-		1,002			-			-			-			1,002
Other comprehensive loss		-		-		-			-			(718	)		-			(718	)
Loss		-		-		-			-			-			(12,679	)		(12,679	)
Balance as of September 30, 2019 (Unaudited)		54,683,807	$	2,099	$	246,554		$	-		$	(2,384	)	$	(225,990	)	$	20,279

(*) Relates to foreign currency translation adjustments.

The accompanying notes are an integral part of the interim consolidated financial statements.

-7-

CYREN LTD.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

($USD in thousands, except share and per share amounts)

(Unaudited)

	Nine months ended September 30,
	2019			2018
	Unaudited
Cash flows from operating activities:
Loss	$	(12,679	)	$	(13,842	)
Adjustments to reconcile loss to net cash used in operating activities:
Loss on disposal of property and equipment		1			14
Depreciation		1,420			1,434
Stock-based compensation		1,002			1,031
Amortization of intangible assets		2,736			3,157
Amortization of deferred commissions		(909	)		1,005
Amortization of operating lease right-of-use assets		1,051			-
Interest on convertible notes		424			-
Other expenses (income) related to the earn-out consideration		(257	)		75
Deferred taxes, net		(182	)		(152	)
Changes in assets and liabilities:
Trade receivables		196			(292	)
Prepaid expenses and other receivables		(607	)		(392	)
Deferred commissions		1,101			(1,797	)
Change in long-term lease deposits		25			(110	)
Trade payables		(264	)		306
Employees and payroll accruals, accrued expenses and other liabilities		(185	)		677
Deferred revenues		5,997			3,040
Accrued severance pay, net		73			(120	)
Operating lease liabilities		(1,075	)		-
Other long-term liabilities		(126	)		71
Net cash used in operating activities		(2,258	)		(5,895	)
Cash flows from investing activities:
Proceeds from sale of property and equipment		1			-
Capitalization of technology, net of grants received		(2,462	)		(1,844	)
Purchase of property and equipment		(1,259	)		(2,989	)
Net cash used in investing activities		(3,720	)		(4,833	)

The accompanying notes are an integral part of the interim consolidated financial statements.

-8-

CYREN LTD.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS – (Continued)

($USD in thousands, except share and per share amounts)

(Unaudited)

	Nine months ended September 30,
	2019			2018
	Unaudited
Cash flows from financing activities:
Payment of earn-out consideration		(2,680	)		(604	)
Proceeds from options exercised		743			1,276
Net cash provided by (used in) financing activities		(1,937	)		672
Effect of exchange rate changes on cash, cash equivalents and restricted cash		(124	)		(39	)
Decrease in cash, cash equivalents and restricted cash		(8,039	)		(10,095	)
Cash, cash equivalents and restricted cash at the beginning of the period		18,156			24,228
Cash, cash equivalents and restricted cash at the end of the period	$	10,117		$	14,133
Supplemental cash flow disclosures:
Cash paid during the year for:
Taxes, net	$	-		$	162
Interest		553			92
Supplemental disclosure of non-cash transactions:
Purchase of property and equipment by credit	$	(1	)	$	(32	)
Issuance of shares for payment of interest on convertible notes		71			-
Net change in accrued payroll expenses related to capitalization of technology		(259	)		(41	)
Reconciliation of cash, cash equivalents and restricted cash as shown in the condensed consolidated statements of cash flow:
Cash and cash equivalents	$	9,546		$	13,527
Restricted cash included in long-term restricted lease deposits		571			606
Total cash, cash equivalents and restricted cash	$	10,117		$	14,133

The accompanying notes are an integral part of the interim consolidated financial statements.

-9-

CYREN LTD.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

($USD in thousands, except share and per share amounts)

(Unaudited)

NOTE 1:- GENERAL

Cyren Ltd. (henceforth “Cyren”) was incorporated under the laws of the State of Israel on February 10, 1991 and its legal form is a company limited by shares. Cyren listed its shares to the public on July 15, 1999 under the name Commtouch Software Ltd. and changed its legal name to Cyren Ltd. in January 2014. Cyren and its subsidiaries, unless otherwise indicated will be referred to in these consolidated financial statements as the “Company”.

The Company is engaged in developing and marketing information security solutions for protecting web, email and mobile transactions. The Company sells its cloud-based solutions worldwide, in both embedded and Security-as-a-Service models, to Original Equipment Manufacturers (“OEMs”), service providers and enterprises. The Company operates in one reportable segment, which constitutes its reporting unit.

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES

a. Interim Financial Statements

The accompanying consolidated balance sheet as of September 30, 2019, the consolidated statements of operations, the consolidated statements of comprehensive loss and the statement of changes in shareholders’ equity for the three and nine months ended September 30, 2019 and 2018, as well as the consolidated statements of cash flows for the nine months ended September 30, 2019 and 2018, are unaudited. These unaudited interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission regarding interim financial reporting. In management’s opinion, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of the Company’s financial position as of September 30, 2019, as well as its results of operations for the three and nine months ended September 30, 2019 and 2018. The results of operations for the three and nine months ended September 30, 2019 are not necessarily indicative of the results to be expected for the year ending December 31, 2019 or for other interim periods or for future years.

b. Over the past several years, the Company has devoted substantially most of its effort to research and development, product development and increasing revenues through additional investments in sales & marketing. The Company generated a loss of $3,530 and $12,679 for the three- and nine-months ending September 30, 2019, negative cash flow of $2,258 from operating activities in the nine months ended September 30, 2019 and has an accumulated deficit of $225,990 as of September 30, 2019. The Company is planning to finance its operations from its existing and future working capital resources and to continue to evaluate additional sources of capital and financing. On September 11, 2019 Cyren announced a rights offering to shareholders of record on September 25 to raise gross proceeds of up to $12,500.  On November 7, 2019 Cyren announced the closing of the offering that raised gross proceeds of $8,019, which will be used toward funding its operations in future quarters.  There is no assurance that additional capital and/or financing will be available to the Company, and even if available, whether it will be on terms acceptable to the Company or in amounts required. Accordingly, the Company’s Board previously approved a contingency plan, to be effected if needed, in whole or in part, at its discretion, to allow the Company to continue its operations and meet its cash obligations. The contingency plan consists of cost reduction, which include mainly the following steps: reduction in consultants’ expenses, headcount, compensation paid to key management personnel and capital expenditures. The Company and the Board believe that its existing capital resources and other future measures that may be implemented, if so required, will be adequate to satisfy its expected liquidity requirements for at least twelve months from the filing date of this Quarterly Report.

-10-

CYREN LTD.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

($USD in thousands, except share and per share amounts)

(Unaudited)

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES (Cont.)

c. Use of estimates:

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the interim consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. On an ongoing basis, the Company’s management evaluates estimates, including those related to fair value and useful lives of intangible assets, fair value of earn-out liabilities, valuation allowance on deferred tax assets, income tax uncertainties, fair values of stock-based awards, other contingent liabilities and estimates used in applying the revenue recognition policy. Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.

d. Significant accounting policies

The accompanying unaudited interim financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 29, 2019.

There have been no changes in the significant accounting policies from those that were disclosed in the audited consolidated financial statements for the fiscal year ended December 31, 2018 included in the 2018 Form 10-K.

e. Recently issued and adopted pronouncements:

In June 2018, the FASB issued ASU No. 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” These amendments expand the scope of Topic 718, Compensation - Stock Compensation (which currently only includes stock-based payments to employees) to include stock-based payments issued to nonemployees for goods or services. Consequently, the accounting for stock-based payments to nonemployees and employees will be substantially aligned. This ASU supersedes Subtopic 505-50, Equity - Equity-Based Payments to Non-Employees. Adoption of this standard had an immaterial impact on the Company’s consolidated financial statements.

-11-

CYREN LTD.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

($USD in thousands, except share and per share amounts)

(Unaudited)

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES (Cont.)

In February 2016, the FASB issued ASU 2016-02, “Leases”, on the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard supersedes the lease requirements in Accounting Standards Codification (ASC) Topic 840, “Leases” and requires lessees, to classify leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for in a manner similar to the accounting under existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. The Company adopted ASU 2016-02 as of January 1, 2019, using the modified retrospective approach. For additional information regarding the Company’s accounting for leases, please refer to Note 3.

f. New accounting pronouncements not yet adopted:

In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. ASU 2017-04 eliminates step two of the goodwill impairment test and specifies that goodwill impairment should be measured by comparing the fair value of a reporting unit with its carrying amount. Additionally, the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets should be disclosed. ASU 2017-04 is effective for annual or interim goodwill impairment tests performed in fiscal years beginning after December 15, 2019, and early adoption is permitted. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements and footnote disclosures.

In August 2018, the FASB issued ASU No. 2018-15, Customer’s Accounting for implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (“ASU 2018-15”). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The update to the standard is effective for interim and annual periods beginning after December 15, 2019, with early adoption permitted. Entities can choose to adopt the ASU 2018-15 prospectively or retrospectively. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements and footnote disclosures.

-12-

CYREN LTD.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

($USD in thousands, except share and per share amounts)

(Unaudited)

NOTE 3:- LEASES

The Company adopted the new standard as of January 1, 2019, using the modified retrospective approach. The modified retrospective approach provides a method for recording existing leases at adoption and in comparative periods that approximates the results of a full retrospective approach. The Company has elected to utilize the available package of practical expedients permitted under the transition guidance within the new standard which does not require it to reassess the prior conclusions about lease identification, lease classification and initial direct costs.

In addition, the Company has elected the short-term lease exception for leases with a term of 12 months or less. As part of this election it will not recognize right-of-use assets and lease liabilities on the balance sheet for leases with terms less than 12 months.

Some leases include one or more options to extend the lease. The exercise of options to extend the lease is typically at the Company’s sole discretion; therefore, the majority of renewals to extend the lease terms are included in our right of use assets and lease liabilities as they are reasonably certain of exercise. The Company regularly evaluates the renewal options, and, when it is reasonably certain of exercise, it will include the renewal period in its lease term. Lease modifications result in remeasurement of the lease liability. 

The right-of-use asset and lease liability are initially measured at the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company’s incremental borrowing rate based on the information available at the date of adoption in determining the present value of the lease payments.

Some of the real estate leases contain variable lease payments based on an index or rate. Variable lease payments based on an index or rate are initially measured using the index or rate in effect at lease adoption. Additional payments based on the change in an index or rate are recorded as a period expense when incurred. 

-13-

CYREN LTD.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

($USD in thousands, except share and per share amounts)

(Unaudited)

NOTE 3:- LEASES (Cont.)

The Company has various operating leases for office space, vehicles that expire through 2030. Below is a summary of our operating right-of-use assets and operating lease liabilities as of September 30, 2019:

Operating lease right-of-use assets	$	8,974
Operating lease liabilities, current	$	1,298
Operating lease liabilities long-term		7,993
Total operating lease liabilities	$	9,291

The short-term lease liabilities are included within accrued expenses and other short-term liabilities in the consolidated balance sheet.

Minimum lease payments for our right of use assets over the remaining lease periods as of September 30, 2019, are as follows:

Year ended December 31,
2019	$	474
2020		1,863
2021		1,759
2022		1,206
2023		1,055
Thereafter		4,299
Total undiscounted lease payments	$	10,656
Less: Interest		1,365
Present value of lease liabilities		9,291

Premises rent expense was $506 and $536 for the three months ended September 30, 2019 and 2018, respectively and $1,469 and $1,428 for the nine months ended September 30, 2019 and 2018, respectively.

As of September 30, 2019, the Company had an additional operating lease that had not yet commenced in the amount of $3,675. This operating lease will commence in the first quarter of 2020 with a lease term through 2029.

The weighted average remaining lease terms and discount rates for all of operating leases were as follows as of September 30, 2019:

Remaining lease term and discount rate:
Weighted average remaining lease term (years)	2.75
Weighted average discount rate	4.16	%

-14-

CYREN LTD.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

($USD in thousands, except share and per share amounts)

(Unaudited)

NOTE 4:- COMMITMENTS AND CONTINGENCIES

a. Cyren Ltd., which was incorporated in Israel, partially financed its research and development expenditures under programs sponsored by the Israel Innovation Authority (“IIA”) for the support of certain research and development activities conducted in Israel.

In connection with specific research and development, the Company received $3,699 of participation payments from the IIA through September 30, 2019. In return for the IIA’s participation in this program, the Company is committed to pay royalties at a rate of 3.5% of the program’s developed product sales, up to 100% of the amount of grants received plus interest at annual LIBOR rate. The Company’s total commitment for royalties payable with respect to future sales, based on IIA participations received, net of royalties paid or accrued, totaled $2,717 and $2,734 as of September 30, 2019 and December 31, 2018 respectively.

b. Litigations:

i.  Between 2014 and 2015 the Company entered into arbitral proceedings with the former shareholders of eleven regarding an escrow account and the earn-out consideration related to the purchase agreement of former eleven. With respect to these claims, on March 9, 2017, the arbitrational panel provided their ruling in which it accepted the claims submitted by the former eleven shareholders with respect to the escrow amount and the 2013 earn-out liability. The arbitrational panel also ruled that Cyren pay legal expenses and interest on the claimed amounts, which were reflected in the year ending December 31, 2016 on the Company’s balance sheet and in the consolidated statements of operations under adjustment to earn-out consideration.   The escrow account has been released to the former shareholders. The arbitrational award related to the 2013 earn-out consideration was declared enforceable by the applicable courts in Germany. Accordingly, on May 30, 2018, the Company paid the portion of the earn-out consideration in the amount of $604 that was declared enforceable by the German district court. The Company did not pay the remainder of the earn-out consideration, including accrued legal and interest, which appear on the Company’s consolidated balance sheets as of December 31, 2018, and has filed an appeal to the German Federal Supreme Court challenging the enforceability of the remaining amounts.   In February 2019, the parties signed a settlement agreement to resolve all pending claims, and on February 28, 2019 the Company paid $2,680 to settle the earn-out consideration in full. The total amount paid to resolve all claims was $256 less than the accrued liability, which generated “other income” as previously reflected in the consolidated statement of operations for the period ending March 31, 2019.

-15-

CYREN LTD.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

($USD in thousands, except share and per share amounts)

(Unaudited)

NOTE 4:- COMMITMENTS AND CONTINGENCIES (Cont.)

ii. On September 28, 2017 a former vendor filed a Statement of Claim in the Tel Aviv District Court (the “SOC”). According to the vendor’s SOC, the Company entered into an agreement with the vendor for receipt of services, based on a database developed by the vendor. In September 2015, the Company terminated the agreement with the vendor, effective as of December 31, 2015. The vendor claims that the Company continues to make use of the vendor’s database post termination, thus breaching the agreement, infringing on the vendor’s rights and commercial secrets, and being unjustly enriched.

The vendor is claiming license fees of approximately $3,150 and an injunction relief ordering the Company and/or its customers to delete any remaining data and to cease from utilizing such data.

The Company denies all claims and filed a Statement of Defense on November 15, 2017. Pretrial was scheduled for May 15, 2018. In accordance with the court’s recommendation from November 28, 2017, the parties agreed to examine a non-binding mediation process and appointed a mediator. The parties agreed to conduct a third-party audit of the Company’s databases in the scope of the mediation and the audit is currently being conducted. At this early stage, the Company is unable to make any estimations as to the outcome of this litigation.

In September 2018 and January 2019, the same vendor filed a lawsuit against two of the Company’s customers in the United States. The vendor alleges that the clients misappropriated the vendor’s trade secrets and is seeking injunctive relief and monetary damages in an amount to be determined. Both customers contended that the allegations relate to the services they received from the Company, and the Company agreed to indemnify both clients against these claims. As such, the Company has taken over the representation in these lawsuits. On September 30, 2019, the court dismissed one of the lawsuits in its entirety for lack of personal jurisdiction and, in the second lawsuit, dismissed part of the claims with prejudice but granted the vendor the right to amend its other claims. On October 31, 2019, the vendor filed an amended complaint. At this early stage, the Company is unable to make any estimations as to the outcome of these litigations.

NOTE 5:- ShareHOLDERS’ EQUITY

a. General:

Ordinary shares confer upon their holders the right to receive notice to participate and vote in general shareholder meetings of the Company and to receive dividends, if declared.

b. Issuance of new convertible notes:

On December 5, 2018 the Company issued $10,000 aggregate principal amount of convertible notes in a private offering. The notes are unsecured, unsubordinated obligations of Cyren and carry a 5.75% interest rate, payable semi-annually in (i) 50% cash and (ii) 50% cash or ordinary shares at Cyren’s election. The notes have a 3-year term and are expected to mature in December 2021, unless converted in accordance with their terms prior to maturity. The notes were issued with a conversion price of $3.90 per share which was subject to adjustment using a weighted average ratchet mechanism based on the size and price of future equity offerings and the total shares outstanding. On November 7, 2019 Cyren announced the closing of a rights offering that raised gross proceeds of $8,019. As a result of this offering, the conversion price of the convertible notes was adjusted to $3.73. In addition, the notes would be subject to immediate conversion upon any change in control in the Company (or subject to repayment if the price in the change in control transaction is less than the conversion price). The Company incurred interest expense for the nine months ended September 30, 2019 of $424. In June 2019, the Company paid the first of the semi-annual interest payments totaling, $287, of which $215 was paid in cash and the remaining portion through the issuance of 35,950 shares.

-16-

CYREN LTD.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

($USD in thousands, except share and per share amounts)

(Unaudited)

NOTE 5:- SHAREHOLDERS’ EQUITY (Cont.)

c. Equity Incentive Plan:

In 1996, the Company adopted the 1996 CSI Share Option Plan for granting options to its U.S. employees and consultants to purchase ordinary shares of the Company, which was replaced in 2006 by the 2006 U.S. Share Option Plan. Until 1999, the Company issued options to purchase ordinary shares to its Israeli employees pursuant to individual agreements. In 1999, the Company approved the 1999 Section 3(i) stock option plan for its Israeli employees and consultants, (which was amended in 2003 and renamed the “Amended and Restated Israeli Share Option Plan”). On December 22, 2016, the Company’s shareholders approved a new stock option plan - the 2016 Equity Incentive Plan (the “Equity Incentive Plan”). This plan, along with its respective Israeli appendix, has replaced all existing employee and consultants stock option plans which have terminated.

The Equity Incentive Plan allows for the issuance of Restricted Share Units (“RSUs”), as well as options. The options and RSUs generally vest over a period of four years. Options granted under the Equity Incentive Plan generally expire after six years from the date of grant. Options and RSUs cease vesting upon termination of the optionee’s employment or other relationship with the Company. The per share exercise price for options shall be no less than 100% of the fair market value per ordinary share on the date of grant. Any options and RSUs that are canceled or not exercised within the option term become available for future grant.

As of September 30, 2019, an aggregate of 6,165,694 ordinary shares of the Company are available for future grant under the Equity Incentive Plan. At the Company’s Annual Meeting on July 30, 2019, our shareholders approved an increase in the number of Ordinary Shares reserved for issuance under the 2016 Equity Incentive Plan and its respective Israeli Appendix to a total of 11,200,000.

d. Non-Employee Directors stock option plan:

In 1999, the Company adopted the 1999 Directors Share Option Plan, and in 2008 shareholders approved an extension of the term of this plan through July 13, 2019. On December 15, 2006, the plan was extended through 2016. On December 22, 2016, the Company’s shareholders approved a new stock option plan - the 2016 Non-Employee Director Equity Incentive Plan (the “Non-Employee Director Plan”). This plan, along with its respective Israeli appendix, has replaced all existing Directors stock option plans which have terminated.

The Non-Employee Director Plan allows for the issuance of Restricted Share Units (“RSUs”), as well as options. Each option and RSU granted under the Non-Employee Plan generally vests over a period of four years. Each option has an exercise price equal to the fair market value of the ordinary shares on the grant date of such option. Options granted under the Non-Employee Director Plan generally expire after six years from the date of grant. Options and RSUs cease vesting upon termination of the relationship with the Company.

As of September 30, 2019, an aggregate of 970,214 ordinary shares of the Company are still available for future grant to non-employee directors. At the Company’s Annual Meeting on July 30, 2019, our shareholders approved an increase in the number of Ordinary Shares reserved for issuance under the Non-Employee Director Plan and its respective Israeli Appendix to a total of 1,150,000 Ordinary Shares.

-17-

CYREN LTD.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

($USD in thousands, except share and per share amounts)

(Unaudited)

NOTE 5:- SHAREHOLDERS’ EQUITY (Cont.)

e. A summary of the Company’s employees and directors’ stock option activity under the plans is as follows:

	Number of options			Weighted average exercise price		Weighted average remaining contractual term (years)		Aggregate intrinsic value
Outstanding at December 31, 2018		6,474,982		$	2.28		3.39	$	4,475
Granted		2,342,500			1.94
Exercised		(470,899	)		1.58
Expired and forfeited		(858,452	)		2.56
Outstanding at September 30, 2019		7,488,131		$	2.19		3.70	$	184
Options vested and expected to vest at September 30, 2019		7,166,054		$	2.23		3.62	$	178
Exercisable options at September 30, 2019		4,260,186		$	2.31		2.41	$	133
Weighted average fair value of options granted during the quarter				$	0.73

As of September 30, 2019, the Company had $2,635 of unrecognized compensation expense related to non-vested stock options granted to employees and directors, expected to be recognized over a remaining weighted average period of 3.15 years.

f. The employee and director options outstanding as of September 30, 2019, have been separated into ranges of exercise prices, as follows:

Outstanding							Exercisable
			Weighted average remaining contractual		Weighted average exercise				Weighted average exercise
	Options		life in		price per		Options		price per
Exercise price per share	outstanding		years		share		exercisable		share
$1.44 - $1.93		1,961,531		4.32	$	1.61		951,031	$	1.57
$2.00 - $2.13		2,402,571		4.30	$	2.06		1,322,571	$	2.03
$2.14 - $2.79		1,634,529		3.23	$	2.48		865,713	$	2.55
$2.90 - $3.07		1,169,000		2.86	$	2.97		812,371	$	2.99
$3.20 - $3.32		320,500		0.79	$	3.32		308,500	$	3.32
		7,488,131		3.70	$	2.23		4,260,186	$	2.31

-18-

CYREN LTD.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

($USD in thousands, except share and per share amounts)

(Unaudited)

NOTE 5:- SHAREHOLDERS’ EQUITY (Cont.)

g Options to non-employees:

Issuance date	Options outstanding		Exercise price per share		Options exercisable		Exercisable through
May 14, 2014		3,000	$	3.32		3,000	May-20
February 18, 2015		3,000	$	3.00		3,000	Feb-21
February 10, 2016		40,000	$	1.44		40,000	Feb-22
January 24, 2017		25,000	$	2.00		25,000	Jan-23
		71,000				71,000

The options vest and become exercisable at a rate of 1/16 of the options every three months.

h. A summary of the Company’s RSUs activity for employees, directors and non-employees under the plans is as follows:

	Number of RSUs			Weighted Average Grant Date Fair Value
Awarded and unvested at December 31, 2018		479,000		$	2.47
Granted		1,421,382			2.00
Vested		(119,750	)		2.47
Forfeited		(42,250	)		2.30
Awarded and unvested at September 30, 2019		1,739,382		$	2.09

As of September 30, 2019, the Company had approximately $3,217 of unrecognized compensation expense related to RSUs, expected to be recognized over a weighted average period of 3.38 years.

-19-

CYREN LTD.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

($USD in thousands, except share and per share amounts)

(Unaudited)

NOTE 5:- SHAREHOLDERS’ EQUITY (Cont.)

i. The total stock-based compensation expense related to all of the Company’s equity-based awards, recognized for the three and nine months ended September 30, 2019 and 2018 was as follows:

	Three months ended September 30,				Nine months ended September 30
	2019		2018		2019		2018
	Unaudited				Unaudited
Cost of revenues	$	36	$	48	$	98		124
Research and development		78		105		203		297
Sales and marketing		51		96		148		293
General and administrative		254		109		553		317
	$	419	$	358	$	1,002	$	1,031

NOTE 6:- SEGMENT AND GEOGRAPHIC INFORMATION

Summary information about geographic areas:

ASC 280, “Segment Reporting,” establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company manages its business on the basis of one reportable segment and derives revenues from licensing of software and sales of professional services, maintenance and technical support (see note 1 for a brief description of the Company’s business). The following is a summary of revenues within geographic areas:

a. The following sets forth total revenue by geographic area based on billing address of the customer:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
United States	$	4,470	$	4,505	$	13,552	$	11,620
Europe		3,043		3,033		9,190		9,635
Asia Pacific		661		733		1,930		2,199
Israel		1,251		1,214		3,971		2,506
Other		71		77		219		428
	$	9,496	$	9,562	$	28,862	$	26,388

-20-

CYREN LTD.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

($USD in thousands, except share and per share amounts)

(Unaudited)

NOTE 6:- SEGMENT AND GEOGRAPHIC INFORMATION (Cont.)

b. Major customers:

During the quarter ended September 30, 2019, 20% of the Company’s revenues were derived from customer A. During the quarter ended September 30, 2018, 20% of the Company’s revenues were derived from customer A.

c. The following sets forth the Company’s property and equipment by geographic area:

	September 30,		December 31
	2019		2018
	Unaudited
Israel	$	1,367	$	1,217
United States		1,701		1,623
Germany		1,096		1,453
Other		273		315
	$	4,437	$	4,608

NOTE 7:- RELATED PARTIES

a. Balances with related parties:

	September 30,		December 31,
	2019		2018
	Unaudited
Prepaid expenses (*)	$	-	$	6

(*) Related to a software license agreement with a related party. See note 7b. for further details.

b. Transactions with related parties:

	Three months ended September 30,				Nine months ended September 30,
	2019		2018		2019		2018
	Unaudited				Unaudited
Software licensing expenses (**)	$	-	$	-	$	-	$	6

(**)  Expenses arising from a software licensing agreement which was executed in March 2017. At the time of execution, the vendor was not a related party. On December 24, 2017, upon completion of the tender offer by WP, the vendor became a related party. The expenses were recorded under research and development expenses net, on the consolidated statements of operations.  The agreement ended March 31, 2019 and has not been renewed.

- - - - - - - - - - - - -

-21-

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the information contained in our consolidated financial statements and the notes thereto. The following discussion and analysis includes forward-looking statements that involve certain risks and uncertainties, including, but not limited to, those described in Item 1A. Risk Factors in our most recent Annual Report on Form 10-K (the “2018 Annual Report”). Our actual results may differ materially from those discussed below. See “Special Note Regarding Forward-Looking Statements” below.

Overview

Purpose built for the cloud, Cyren is an early pioneer and leading innovator of SaaS security solutions that protect businesses and their employees and customers from threats on the web, in email and on mobile devices. Our mission is to protect people and organizations from cyber threats when they use the internet.

Cyren’s cloud-first approach to security sets us apart from other vendors in the market. Cyren is an internet security company that is delivering security results that are disrupting legacy vendors and appliance-based solutions. Our security solutions are architected around the fundamental belief that internet security is a race against time – and the cloud best enables the speed, sophistication and advanced automation needed to detect and block threats as they emerge on the internet.

Cyren’s security cloud delivers faster detection and protection, with SaaS security solutions that inspect web and email traffic before it reaches a user’s browser or inbox – often identifying and blocking threats in just seconds. Our SaaS solutions are easy to deploy and manage, delivering critical security and faster innovation, for a low total cost of ownership.

Cyren’s cloud security services are sold into two markets:

● Cyren Cloud Security (CCS) – this SaaS security platform is designed for enterprise customers and is sold either directly or through channel partners. Cyren Cloud Security (CCS) services currently include Email Security (CES), Web Security (CWS), DNS Security, and Cloud Sandboxing. Each of these service offerings may be purchased separately, or as part of a bundled suite. All products are sold on a per-user SaaS subscription model, providing customers with a quick-to-deploy, easy-to-manage solution and a low total cost of ownership. We market and sell our solutions worldwide both directly through our sales teams and indirectly through our Partner Program where our sales organization actively assists our network of distributors and resellers.   During the first half of 2019, Cyren decided to focus its product development and sales efforts on products that are derived from its Cloud Email Security solutions, and as such, will be de-emphasizing standalone and bundled Web Security (CWS) offerings. The Company will continue to support existing CWS customers through the end of 2020 but is no longer pursuing new sales of these services.   Since 2018, Cyren has been developing an anti-phishing solution targeted at enterprise customers in a market segment that Gartner has defined as Cloud Email Security Supplements (CESS). Cyren’s CESS solution, which has been internally branded as Cyren Inbox Security (CIS), is expected to be generally available during the first half of 2020, and is not expected to have any revenue impact until 2020.

● Cyren Threat Intelligence Services (TIS) – this platform offers cloud-based cyber threat detection APIs, and SDKs to many of the world’s leading technology and security vendors. Cyren Threat Intelligence Services include Email Security, Web Security, Endpoint Security, and Advanced Threat Protection. These solutions are sold directly to Original Equipment Manufacturers (“OEMs”), embedded security vendors, and service providers that integrate Cyren Threat Intelligence Services and cloud detection services into their infrastructure or security products to protect their customers and users.

Key Opportunities and Challenges

Threat Landscape

Over the last several years, possibly the greatest magnitude of significant incidents directly related to malware and cyber threats have occurred since the advent of the internet. From election hacks to global ransomware attacks and cyber breaches, malware threats are at an all-time high. Today, no item or user connected to the internet is immune to attack. While many businesses are still exploring effective security measures, cybercriminals are “all in”, creating dangerous new tools to target companies, governments, and private citizens. We need to be mindful that the world has changed; hyper-evasive malware and threat distribution via HTTPS are growing rapidly, mobile devices are increasingly targets, and Internet of Things (IoT) devices, from refrigerators to televisions, are an inviting new vector for criminal attacks. 

-22-

Cloud and Mobility

Businesses are going through a massive change in their IT strategies as they look to drive more business value, agility, and better customer experiences, while cloud and mobility are becoming increasingly important, as evidenced by the following trends:

● Business internet traffic continues to increase every year;

● Data and applications are increasingly moving to the cloud;

● More and more users are working remotely;

● Buyers continue to move away from traditional on-premise solutions;

● Mature and legacy on premise deployments are reaching end of life and are increasingly being replaced by cloud and SaaS alternatives;

● IT security staffing shortages;

● Increasingly fast, sophisticated, expensive and high-profile attacks target organizations of all sizes;

● Compliance and regulatory mandates;

● Heightened cybercrime activity among commercial enterprises and nation states;

● Automation is increasingly considered critical to accelerating detection and protection; and

● The need to simplify operations through vendor consolidation.

These are some of the reasons why we believe Cyren’s vision for 100% cloud security is compelling to IT security teams looking to protect their businesses in today’s cloud-centric mobile-first world.

Investments in Operations, Research and Development and Sales and Marketing

Our cost of revenues, research and development (“R&D”) expenses, and sales and marketing expenses are all significant contributing factors to our operating losses. Nonetheless, we expect to increase our investments in all three areas in order to grow our revenues. Over time, we expect that our utilization of our cloud infrastructure will increase and provide the opportunity for improved gross margins. Our investments in R&D are required in order to enhance and improve our solutions. In the future, we expect to lower the rate of R&D investment as a percentage of revenue, and we will be able to drive more revenue from existing solutions rather than by adding new solutions. The return on our sales and marketing investment is tied to attracting new customers and enhancing our business with existing customers, thereby lowering the overall sales and marketing costs as a percent of revenues. Finally, we continue to increase our headcount to support the growth of the business, but we expect that reducing the historical rate of headcount growth will be key in improving our gross and operating margins over time.

Growing Our Enterprise SaaS Business

Although all of our services are subscription services, our Enterprise Security-as-a-Service offerings on the CCS platform are typically invoiced up front for an annual contract amount, or the full multi-year contract amount, at the start of the term. As a result, this business is expected to provide a larger immediate contribution to cash flow and better return on investment. As this enterprise business grows as a portion of our overall revenues, we expect to increase deferred revenue and our operating results and cash flow to improve, which will make us less reliant on other sources of capital in the future.

Components of our Operating Results

Revenue

We derive revenues from the sale of real-time cloud-based services for each of Cyren’s email security, web security, antimalware and advanced threat protection offerings.

-23-

We sell all of our solutions as subscription services, either through OEMs and service providers, which are considered Cyren customers, or as complete security services directly, or indirectly via our partners, to enterprises.

Cost of Revenues

Personnel costs, which consist of salaries, benefits, bonuses and stock-based compensation for employees that operate our network and provide support services to our customers, as well as data center costs, are the most significant components of our cost of revenues. Other costs include third party contractors, royalties for use of third-party technologies, amortization of intangibles and depreciation of data center equipment. We expect these costs to continue to increase in absolute dollars as we continue to invest in enhancing our cloud infrastructure and our support services.

Operating Expenses

Our operating expenses consist of R&D, sales and marketing, and general and administrative expenses. Personnel costs, which consist of salaries, benefits, bonuses, and stock-based compensation, are the most significant component of our operating expenses. Operating expenses also include allocated overhead costs for facilities, IT and depreciation. We expect operating expenses to increase in absolute dollars as we continue to grow.

Research and Development. R&D expense consists primarily of personnel costs, outsourced engineering and threat analysis services. We believe these investments are crucial for our ability to continue to enhance the functionality of our services, as well as to develop and introduce new services to the market. We expect R&D expenses to continue increasing in absolute dollars as we continue to invest in our service offerings. Development costs related to internal use technology that supports our security services are capitalized on the balance sheet, while other development costs are expensed as they are incurred.

Sales and Marketing. Sales and marketing expenses primarily include personnel costs, sales commissions, marketing activities, and travel associated with sales and marketing. We market and sell our services worldwide through our sales organization and distribution channels. We capitalize sales commissions paid to internal sales personnel and amortize these expenses over an estimated period of benefit that reflects the expected future revenue streams. We expect our sales and marketing expenses to continue to increase in absolute dollars as we continue to enhance our sales and marketing teams to support our further growth. Our sales personnel are typically not immediately productive, and therefore the increase in expenses we incur when adding personnel is not immediately accompanied by increased revenue and in some cases may not result in increased revenue if these new sales personnel are unsuccessful in becoming productive.

General and Administrative. General and administrative expenses consist primarily of personnel costs, audit fees, legal expenses, recruiting expenses and other general operating costs. We expect our general and administrative expenses to continue to grow in absolute dollars as we continue our operational growth.

Other Income (Expense), net

Other income (expense), net consists primarily of capital gain or loss from the sale of assets.

Financial Expenses, net

Financial expenses, net consist mainly of foreign exchange gains and losses, interest expense on our outstanding debt and interest income earned on our cash and cash equivalents.

Tax Benefit

Our tax benefit is derived primarily from income taxes in foreign jurisdictions in which we conduct business. We estimate income taxes in each of the jurisdictions in which we operate. This process involves determining income tax expense together with calculating the deferred income tax expense related to temporary differences resulting from the differing treatment of items for tax and accounting purposes. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. These temporary differences result in deferred tax assets and liabilities, which are included net as applicable within our balance sheets. For most of our recent years, we have incurred operating losses in Israel and the U.S., where we have recorded a full valuation allowance against our deferred tax assets in those jurisdictions.

-24-

RESULTS OF OPERATIONS

The following table sets forth financial data for the three and nine months ended September 30, 2019 and 2018. Percentages may not add due to rounding.

	Three months ended September 30												Nine months ended September 30
	2019			%			2018			%			2019			%			2018			%
	Unaudited						Unaudited						Unaudited						Unaudited
Revenues	$	9,496			100	%	$	9,562			100	%	$	28,862			100	%	$	26,388			100	%
Cost of revenues		3,712			39	%		3,670			38	%		11,501			40	%		10,684			40	%
Gross profit		5,784			61	%		5,892			62	%		17,361			60	%		15,704			60	%
Operating expenses:
Research and development, net		3,516			37	%		4,336			45	%		11,990			42	%		11,355			43	%
Sales and marketing		3,027			32	%		3,931			41	%		10,473			36	%		12,133			46	%
General and administrative		2,484			26	%		2,166			23	%		7,314			25	%		6,151			23	%
Total operating expenses		9,027			95	%		10,433			109	%		29,777			103	%		29,639			112	%
Operating loss		(3,243	)		-34	%		(4,541	)		-47	%		(12,416	)		-43	%		(13,935	)		-53	%
Other income (expense), net		(3	)		0	%		-			0	%		262			1	%		(17	)		0	%
Financial expense, net		(321	)		-3	%		7			0	%		(642	)		-2	%		(91	)		0	%
Loss before taxes		(3,567	)		-38	%		(4,534	)		-47	%		(12,796	)		-44	%		(14,043	)		-53	%
Tax benefit		37			0	%		107			1	%		117			0	%		201			1	%
Net loss	$	(3,530	)		-37	%	$	(4,427	)		-46	%	$	(12,679	)		-44	%	$	(13,842	)		-52	%

-25-

Three and Nine Months Ended September 30, 2019 Compared to the Three and Nine Months Ended September 30, 2018

Revenues. Revenues decreased $0.1 million or 1%, and increased $2.5 million or 9%, respectively, for the three and nine months ended September 30, 2019 as compared to the corresponding periods last year. The year over year increase was primarily driven by contract expansions with a large Threat Intelligence customer which was signed during the fourth quarter of 2018, as well as new and upsell contracts in the enterprise business during the second half of 2018. These increases were offset by a small number of customer terminations in the Threat Intelligence and enterprise businesses, but overall contract renewal rates were consistent with prior periods.

Cost of Revenues. Cost of revenues for the three and nine months ended September 30, 2019 increased $0.0 million, or 1%, and $0.8 million or 8%, respectively, as compared to the corresponding periods last year.

For the three months ended September 30, 2019 cost of revenues represented 39% of revenue, compared to 38% during the prior year, and accordingly gross margins for the period were 61% for the three months ended September 30, 2019 compared to 62% for the same period in the prior year. For the nine months ended September 30, 2019 cost of revenues represented 40% of revenue, compared to 40% during the prior year, and accordingly gross margins for the period were 60% for the nine months ended September 30, 2019 compared to 60% for the same period in the prior year. The increase in cost of revenues is the result of continued investment in our global network and data centers, as well as additional payroll expense in our Support and Operations groups compared to the prior year. During the period, there was a slight decrease in amortization of capitalized development expenses for the three and nine months ended September 30, 2019 to $0.8 million from $0.9 million and to $2.4 million from $2.7 million during the prior year, respectively.

Operating Expenses. Overall operating expenses decreased $1.4 million or 13%, and increased $0.1 million or 0%, respectively, for the three and nine months ended September 30, 2019 as compared to the corresponding periods last year.

Operating expenses for the three months ended September 30, 2019 represented 95% of revenue, compared to 109% during the prior year. For the nine months ended September 30, 2019, operating expenses represented 103% of revenue, compared to 112% during the prior year. The decrease in the quarter over quarter operating expenses was primarily due to a decrease in employee headcount by seven employees in Q3 2019 from Q2 2019, whereas Q3 2018 from Q2 2018 saw an increase by 20 employees. Overall, within R&D and operating expenses, there were 255 employees at the end of September 30, 2019, compared to 251 employees at the end of September 30, 2018, which accounted for the slight increase in year-to-date expenses.

-26-

Research and Development, Net. Research and development expenses, net decrease $0.8 million, and increased $0.6 million or 6%, respectively for the three and none months ended September 30, 2019 as compared to the corresponding periods last year. R&D expense, net for the three months ending September 30, 2019 represented 37% of revenue, compared to 45% a year ago. For the nine months ending September 30, 2019, R&D expense, net represented 42% of revenue compared to 43% a year ago. The increase in R&D expense is primarily driven by increased employee headcount, higher payroll and an increase in outsourced development compared to the same period in 2018. Capitalization of technology development increased to $1.2 million for the three months ended September 30, 2019 from $0.2 million for the three months ended September 30, 2018 and to $2.6 million from $1.9 million for the nine months ended September 30, 2019 and 2018, respectively.

Sales and Marketing. Sales and marketing expenses decreased $0.9 million, or 23%, and $1.7 million, or 14%, respectively, for the three and nine months ended September 30, 2019, as compared to the corresponding periods last year. Sales and marketing expense for the three months ending September 30, 2019 represented 32% of revenue, compared to 41% a year ago. For the nine months ending September 30, 2019, sales and marketing expense represented 36% of revenue compared to 46% a year ago. The decrease in sales and marketing expense was primarily due to a reduction of overall sales and marketing headcount by six employees at the end of the third quarter 2019 compared to the same period a year ago, as well as a reduction in overall marketing spend related to advertising and industry trade shows.

General and Administrative. General and administrative (G&A) expenses increased $0.3 million, or 15%, and $1.2 million, or 19%, respectively, for the three and nine months ended September 30, 2019, as compared to the corresponding periods last year. G&A expense for the three months ending September 30, 2019 represented 26% of revenue, compared to 23% a year ago. For the nine months ending September 30, 2019, sales and marketing expense represented 25% of revenue compared to 23% a year ago. The increase in G&A expense is mainly due to an increase in legal costs, as well as additional stock-based compensation related to the change in CEO that occurred in the second quarter of 2019.

Other Income (Expense), Net. Other income, net for the nine months ended months ended September 30, 2019 was $0.2 million, compared to an expense of $0.0 million for corresponding periods last year. During the first quarter of 2019, we reached a financial settlement with the former shareholders of eleven related to the legal dispute regarding the amount and timing of the earn-out payments related to the acquisition of eleven (the “eleven settlement”). Since the financial settlement was less than the accrued interest and the unpaid earn-out consideration on the Company’s balance sheet, the difference was reflected as other income during the period. For additional information, please refer to Note 4 of the consolidated financial statements included elsewhere in this quarterly report on Form 10-Q (the “Quarterly Report”).

Financial Expense, Net. Financial expenses, net, increased $0.3 million, or 4,686%, and $0.5 million, or 605%, respectively, for the three and nine months ended September 30, 2019, as compared to the corresponding periods last year. The increase in expense is due mainly to an increase in interest expenses associated with the convertible notes issued in December 2018, the associated interest expense for the three and nine months ended September 30, 2019 was $0.1 million and $0.4 million. For additional information, please refer to Note 5 of the consolidated financial statements included elsewhere in this Quarterly Report. In addition, during the three and nine months ended September 30, 2019 we also recorded expense of $0.2 million and $0.3 million resulting from the effect of foreign currency exchange rate fluctuation.

Effective Corporate Tax Rates

Corporate tax rates and real capital gains tax in Israel were 23% for the three months ended September 30, 2019 and 2018.

Our German subsidiary is subject to German tax at a consolidated rate of approximately 30%.

Other non-Israeli subsidiaries are taxed according to the tax laws in their respective countries of residence.

We do not provide deferred tax liabilities when we intend to reinvest earnings of foreign subsidiaries indefinitely. As of September 30, 2019, there are no undistributed earnings of foreign subsidiaries. 

-27-

We may currently qualify as an “industrial company” within the definition of the Law for the Encouragement of Industry (Taxation) and, as such, we may be eligible for certain tax benefits, including, inter alia, special depreciation rates for machinery, equipment and buildings, amortization of patents, certain other intangible property rights and deduction of share issuance expenses.

Net Operating Loss Carry-Forwards

As of December 31, 2018, Cyren’s net operating loss carryforwards for tax purposes amounted to $80.1 million and capital loss carryforwards of $17.8 million which may be carried forward and offset against taxable income in the future, for an indefinite period.

As of December 31, 2018, the U.S. subsidiary had net operating loss carryforwards of $40.3 million for federal tax purposes and $8.8 million for state tax purposes. These losses may offset any future U.S. taxable income of the U.S. subsidiary and will expire in the years 2019 through 2038.

On December 24, 2017, a “change in the respective ownership” event occurred upon the completion of a tender offer of our ordinary shares by an entity controlled by funds affiliated with Warburg Pincus LLC (“Warburg Pincus”), and in accordance with the relevant provisions of the Internal Revenue Code 382 of 1986 and similar state provisions. Therefore, our utilization of U.S. net operating losses are subject to substantial annual limitations. Management believes that the annual limitations will result in the partial expiration of net operating losses before utilization.

Management currently believes that based upon its estimations for future taxable income, it is more likely than not that the deferred tax assets regarding the loss carryforwards will not be utilized in the foreseeable future. Thus, a valuation allowance was provided to reduce deferred tax assets to their realizable value.

LIQUIDITY AND CAPITAL RESOURCES

We finance our operations primarily from our cash and cash equivalents and cash from operations. As of September 30, 2019, and December 31, 2018, we had approximately $9.5 million and $17.6 million of cash and cash equivalents, respectively.

Our future capital requirements will depend on many factors, including, but not limited to our growth, market acceptance of our offerings, the timing and extent of spending to support our efforts to develop our platform and the expansion of sales and marketing activities. We may be required to seek additional equity or debt financing. In the event that additional financing is required from outside sources, we may not be able to raise it on terms acceptable to us or at all. If we are unable to raise additional capital when desired, our business, financial condition and results of operations could be adversely affected.

Outlook

During 2019, we expect to continue to incur capital expenditures associated with R&D and data center infrastructure.  We generated a loss of $3.5 and $12.7 million for the three- and nine-months ending September 30, 2019 and negative cash flow of $2.3 million from operating activities in the nine months ending September 30, 2019 and have an accumulated deficit of $226.0 million as of September 30, 2019. We are planning to finance our operations from our existing and future working capital resources and to continue to evaluate additional sources of capital and financing. On September 11, 2019 Cyren announced a rights offering to shareholders of record on September 25 to raise gross proceeds of up to $12.5 million. On November 7, 2019 Cyren announced the closing of the offering that raised gross proceeds of $8.0 million, which will be used toward funding its operations in future quarters. There is no assurance that additional capital and/or financing will be available to us, and even if available, whether it will be on terms acceptable to us or in amounts required. Accordingly, our Board previously approved a contingency plan, to be effected if needed, in whole or in part, at its discretion, to allow us to continue our operations and meet our cash obligations. The contingency plan consists of cost reduction, which include mainly the following steps: reduction in consultants’ expenses, headcount, compensation paid to key management personnel and capital expenditures. We and the Board believe that our existing capital resources and other future measures that may be implemented, if so required, will be adequate to satisfy our expected liquidity requirements for at least twelve months from the filing date of this Quarterly Report.

-28-

Cash Flows from Operating Activities

Cash used in operating activities was $2.3 million for the nine months ended September 30, 2019 as compared to $5.9 million for the nine months ended September 30, 2018. The decrease in cash usage of $3.6 million was primarily due to one large 36-month and one large 12-month prepayment from two of Cyren’s largest Threat Intelligence customers during the first and second quarters of 2019, respectively. The prepayments are reflected on the balance sheet as an increase in short-term and long-term deferred revenue.

Cash Flows from Investing Activities

Cash used in investing activities was $3.7 million for the nine months ended September 30, 2019 as compared to $4.8 million for the nine months ended September 30, 2018. The decrease of $1.1 million was primarily due to a decrease in capital expenditures compared to the same period a year ago.

Cash Flows from Financing Activities

Cash used in financing activities was $1.9 million for the nine months ended September 30, 2019 as compared to cash provided of $0.7 million for the nine months ended September 30, 2018. The increase of $2.6 million was primarily due to a payment of $2.7 million in conjunction with the eleven settlement which occurred in the first quarter of 2019. The eleven settlement was offset by a decrease in 2019 of $0.5 million generated from the exercise of stock options in the period.

Working Capital

As of September 30, 2019, we had negative working capital of $2.2 million and as of September 30, 2018, we have positive $2.1 million, respectively. The decrease in working capital during the nine months ended September 30, 2019 as compared to the prior year is primarily due to our negative cash flow from operations and lower amounts of capital raised during the fourth quarter of 2018 and in 2019 compared to amounts of capital raised during the fourth quarter of 2017.

Convertible Notes

On December 5, 2018, we issued an aggregate $10.0 million principal amount of convertible notes in a private placement (the “Notes”) to affiliates of an existing minority institutional shareholder. The Notes are unsecured, unsubordinated obligations of Cyren and carry a 5.75% interest rate, payable semi-annually in (i) 50% cash and (ii) 50% cash or ordinary shares at Cyren’s election. The Notes have a 3-year term and mature in December 2021, unless converted in accordance with their terms prior to maturity. The Notes had a conversion price of $3.90 per share, which was subject to adjustment using a weighted average ratchet mechanism based on the size and price of future capital raises and the total shares outstanding. As a result of the Company’s rights offering which closed on November 6, 2019, the conversion price of the convertible notes was adjusted to $3.73. In addition, the Notes would be subject to immediate conversion upon any change in control in the Company (or subject to repayment if the price in the change in control transaction is less than the conversion price). The Company incurred interest expense for the nine months ended September 30, 2019 of $0.4 million. In June 2019, the Company paid the first of the semi-annual interest payments totaling, $0.3 million, of which $0.2 was paid in cash and the remaining portion through the issuance of 35,950 shares.

Earn-Out Consideration

In conjunction with the 2012 acquisition of eleven, we entered into an earn-out agreement with the former shareholders that would pay additional consideration based on the revenue performance for the years ending 2012-2015. Subsequently in 2014, we had a legal dispute regarding the amount and timing of the earn-out payments and had entered into arbitral proceedings with the former shareholders of eleven. On March 9, 2017, we received the arbitral judgement. Pursuant to the judgement, the earn-out consideration balance was increased to reflect additional legal expenses and interest expenses covering the period up to December 31, 2016. During 2017 and 2018, we continued to accrue interest on the unpaid earn-out consideration balance. Such interest is reflected in the consolidated statements of operations under financial expenses, net. In May 2018, we made a partial payment of the earn-out consideration to five of the six former shareholders, in an amount of $0.6 million. The earn-out consideration balance presented on our balance sheet as of December 31, 2018 reflected the complete remaining liability relating to the earn-out, including accrued interest. In February 2019, the parties agreed to resolve all pending claims, and on February 28, 2019, we paid approximately $2.7 million to settle the earn-out consideration in full. For additional information, please refer to Note 4 of the consolidated financial statements included elsewhere in this Quarterly Report.

-29-

Registration Statements

In connection with a previously disclosed private placement in November 2017 in which we issued approximately 10.6 million ordinary shares to an entity controlled by funds affiliated with Warburg Pincus, we and Warburg Pincus entered into a registration rights agreement which, among other things, provides Warburg Pincus with three demand registration rights, piggyback and shelf registration rights. The demand registration rights became exercisable as of August 6, 2018, subject to certain customary blackout periods. In addition, as of November 6, 2019, we will be required to file a shelf registration statement covering the sale of Warburg Pincus’s shares if requested by Warburg Pincus.

On September 21, 2018 we filed a shelf registration statement on Form F-3 with the Securities and Exchange Commission (“SEC”), which we converted to a Form S-3 on August 16, 2019. This registration statement enables us to issue debt securities, ordinary shares, warrants or subscription rights up to an aggregate amount of $50 million. Under the rules governing shelf registration statements, we are now able to file prospectus supplements with the SEC which describe the amount and type of securities being offered each time we issue securities under the registration statement. No securities were issued under the registration statement on Form F-3. In November 2019, we issued shares as part of our rights offerings using our Form S-3 as described below.

Rights Offering

In October 2019, the Company announced that it commenced the previously announced rights offering to raise gross proceeds of approximately $12.5 million (the “Rights Offering”). Under the terms of the Rights Offering, the holders of the Company’s ordinary shares as of 5:00 p.m., New York City time, on September 25, 2019, the record date for the Rights Offering, received one subscription right (a “Right”) for every 7.55 ordinary shares held, as more fully described in the prospectus supplement to our Form S-3 filed with the SEC. Each Right entitled a holder to purchase one ordinary share at a subscription price of $1.73 per share. A maximum of 7,240,808 ordinary shares could be issued pursuant to the Rights Offering, representing approximately 13.2% of the currently issued and outstanding ordinary shares. No fractional Rights were issued in the Rights Offering; any fractional Rights were rounded down to the nearest whole Right. The Rights Offering also included an over-subscription right which entitled all shareholders to purchase additional ordinary shares that remain unsubscribed for at the expiration of the Rights Offering. The Company expects to use the proceeds from the Rights Offering for general working capital purposes.

The Company’s majority shareholder, WP XII Investments B.V., an entity controlled by funds affiliated with Warburg Pincus, LLC (“Warburg Pincus”) provided a commitment to the Company in which it committed to subscribe for ordinary shares for an aggregate amount of at least $8,000,000 of ordinary shares pursuant to its basic subscription rights and over-subscription rights. Warburg Pincus did not receive any fee in connection with its commitment.

On November 7, 2019 Cyren announced the closing of the offering that raised gross proceeds of $8,019,560, which will be used toward funding its operations in future quarters.

Off-Balance Sheet Arrangements

As of September 30, 2019, we did not have any off-balance sheet arrangements. 

Critical Accounting Policies and Estimates

Our significant accounting policies are discussed in Note 2. Significant Accounting Policies to our consolidated financial statements included in the Company’s Form 10-K filed with the Securities and Exchange Commission on March 29, 2019. There have been no significant changes to these policies for the nine months ended September 30, 2019, except as described in Note 2. Significant Accounting Policies to our condensed consolidated financial statements are included elsewhere in this Quarterly Report. The critical accounting policies requiring estimates, assumptions, and judgements that we believe have the most significant impact on our consolidated financial statements are described in Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our 2018 Annual Report.

Recent Accounting Pronouncements

Please refer to Note 2. Significant Accounting Policies to our condensed consolidated financial statements included elsewhere in this Quarterly Report for a full description of recent accounting pronouncements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not required for smaller reporting companies.

Special Note Regarding Forward-Looking Statements

This Quarterly Report contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These statements concern expectations, beliefs, projections, plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. We urge you to consider that statements which use the terms “anticipate,” “believe,” “expect,” “plan,” “intend,” “estimate”, “will” and similar expressions are intended to identify forward-looking statements. Specifically, this Quarterly Report contains forward-looking statements regarding:

● our expectations regarding increases in cost of revenue and operating expenses, including as a result of our anticipated investments in R&D;

● our expectations regarding the timing of availability of our CIS solution to the market and the timing of its revenue impact;

-30-

● our beliefs regarding the importance of R&D;

● our expectation to lower the rate of R&D investment as a percentage of revenue in the future and to drive more revenue from existing solutions rather than by adding new solutions;

● our expectations regarding reducing the historical rate of headcount growth and its resulting impact on our gross and operating margins over time;

● our expectations regarding our business strategies, including our contingency plan;

● our expectations regarding growth of our enterprise business and its expected impact on our business and operating results, including its contribution to our cash flow and return on investment;

● our expectations regarding our capital expenditures for 2019;

● our belief regarding the adequacy of our existing capital resources and other future measures to satisfy our expected liquidity requirements;

● our anticipated increases in investments to grow our revenue;

● our beliefs and expectations regarding existing and new threats, key challenges and opportunities in our industry and their impact on our business;

● our expectations regarding the increase in utilization of our cloud infrastructure and the resulting impact on our gross margins;

● our beliefs regarding factors that make our vision compelling to the IT security market;

● our beliefs regarding our net operating loss carry-forwards; and

● our expectations and estimates regarding certain tax and accounting matters, including the impact on our financial statements.

These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. The most important factors that could prevent us from achieving our goals, and cause the assumptions underlying forward-looking statements and the actual results to differ materially from those expressed in or implied by those forward-looking statements include, but are not limited to, the following:

● our ability to execute our business strategies;

● lack of demand for our solutions, including as a result of actual or perceived decreases in levels of advanced cyber attacks;

● our ability to manage our cost structure, avoid unanticipated liabilities and achieve profitability;

● our ability to grow our revenues, including the ability of existing solutions to drive sufficient revenue;

● our ability to attract new customers and increase revenue from existing customers;

● market acceptance of our existing and new product offerings;

● our ability to adapt to changing technological requirements and shifting preferences of our customers and their users;

● our ability to successfully shift the focus of our product development and sales efforts to our CES solutions, while de-emphasizing our CWS offerings;

● loss of any of our large customers;

-31-

● adverse conditions in the national and global financial markets;

● the impact of currency fluctuations;

● political and other conditions in Israel that may limit our R&D activities;

● our ability to successfully implement our contingency plan, if needed, and its ability to allow us to continue our operations and meet our cash obligations;

● our ability to comply with applicable laws and regulations and the impact of changes in applicable laws and regulations, including tax legislation or policies; 

● economic, regulatory and political risks associated with our international operations;

● the impact of our controlling shareholder’s decisions, which may differ with respect to our strategic direction; and

● our ability to successfully estimate the impact of certain accounting and tax matters, including the effect on our company of adopting certain accounting pronouncements.

The foregoing list of important factors does not include all such factors, nor necessarily present them in order of importance. In addition, you should consult other disclosures made by us (such as in our other filings with the SEC or in company press releases) for other factors that may cause actual results to differ materially from those projected by us. Please refer to Part I. Item 1A. Risk Factors, of our 2018 Annual Report for additional information regarding factors that could affect our results of operations, financial condition and liquidity.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, including the securities laws of the United States, we undertake no obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances, or otherwise after the date hereof. 

ITEM 4. CONTROLS AND PROCEDURES

Management’s Evaluation of Disclosure Controls and Procedures

In order to ensure that the information we must disclose in our filings with the SEC is recorded, processed, summarized and reported on a timely basis, we have formalized our disclosure controls and procedures. Our principal executive officer and principal financial officer have reviewed and evaluated the effectiveness of our disclosure controls and procedures, as defined in Securities and Exchange Act Rules 13a-15(e) and 15d-15(e) as of September 30, 2019. Based on such evaluation, such officers have concluded that, as of September 30, 2019, our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

There were no changes to our internal control over financial reporting, as defined in Securities and Exchange Act Rules 13a-15(f) and 15d-15(f), that occurred during the quarter ended September 30, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

-32-

PART II – OTHER INFORMATION.

ITEM 6. EXHIBITS

Exhibit No.	Description of Exhibits
31.1	Certification by Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification by Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification by Chief Executive Officer and Chief Financial Officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	XBRL Instance Document.
101.SCH	XBRL Taxonomy Extension Schema Document.
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document.
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document.
101.LAB	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.

-33-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CYREN LTD.
November 13, 2019	/s/ Brett Jackson
	Brett Jackson Chief Executive Officer
	(Duly Authorized Officer)

November 13, 2019	/s/ J. Michael Myshrall
	J. Michael Myshrall Chief Financial Officer
	(Principal Financial Officer)

-34-

EX-31.1

Exhibit 31.1

CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Brett Jackson, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Cyren Ltd.

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:  November 13, 2019

By:	/s/ Brett Jackson
	Brett Jackson Chief Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATION BY THE CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, J. Michael Myshrall, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Cyren Ltd.

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 13, 2019

By:	/s/ J. Michael Myshrall
	J. Michael Myshrall Chief Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Cyren Ltd. (the “Company”) for the period ended September 30, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Brett Jackson, Chief Executive Officer, and J. Michael Myshrall, Chief Financial Officer, of the Company, do each certify, pursuant to Section 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge:

1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. the information contained in the Report fairly presents, in all materials respects, the financial condition and results of operations of the Company.

Date: November 13, 2019

By:	/s/ Brett Jackson
	Brett Jackson Chief Executive Officer
By:	/s/ J. Michael Myshrall
	J. Michael Myshrall Chief Financial Officer

XML

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) $ in Thousands	Sep. 30, 2019 USD ($) shares	Sep. 30, 2019 ₪ / shares	Dec. 31, 2018 USD ($) shares	Dec. 31, 2018 ₪ / shares
Statement of Financial Position [Abstract]
Allowances for doubtful accounts | $	$ 21		$ 20
Prepaid expenses attributable to related parties | $	$ 0		$ 6
Ordinary shares, par value | ₪ / shares		₪ 0.15		₪ 0.15
Ordinary shares, authorized	110,000,000		75,353,340
Ordinary shares, issued	54,683,807		54,405,881
Ordinary shares, outstanding	54,683,807		54,057,208
Treasury shares	0		348,673

XML

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities:
Loss	$ (12,679)	$ (13,842)
Adjustments to reconcile loss to net cash used in operating activities:
Loss on disposal of property and equipment	1	14
Depreciation	1,420	1,434
Stock-based compensation	1,002	1,031
Amortization of intangible assets	2,736	3,157
Amortization of deferred commissions	(909)	1,005
Amortization of operating lease right-of-use assets	1,051
Interest on convertible notes	424
Other expenses (income) related to the earn-out consideration	(257)	75
Deferred taxes, net	(182)	(152)
Changes in assets and liabilities:
Trade receivables	196	(292)
Prepaid expenses and other receivables	(607)	(392)
Deferred commissions	1,101	(1,797)
Change in long-term lease deposits	25	(110)
Trade payables	(264)	306
Employees and payroll accruals, accrued expenses and other liabilities	(185)	677
Deferred revenues	5,997	3,040
Accrued severance pay, net	73	(120)
Operating lease liabilities	(1,075)
Other long-term liabilities	(126)	71
Net cash used in operating activities	(2,258)	(5,895)
Cash flows from investing activities:
Proceeds from sale of property and equipment	1
Capitalization of technology, net of grants received	(2,462)	(1,844)
Purchase of property and equipment	(1,259)	(2,989)
Net cash used in investing activities	(3,720)	(4,833)
Cash flows from financing activities:
Payment of earn-out consideration	(2,680)	(604)
Proceeds from options exercised	743	1,276
Net cash provided by (used in) financing activities	(1,937)	672
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(124)	(39)
Decrease in cash, cash equivalents and restricted cash	(8,039)	(10,095)
Cash, cash equivalents and restricted cash at the beginning of the period	18,156	24,228
Cash, cash equivalents and restricted cash at the end of the period	10,117	14,133
Supplemental cash flow disclosures:
Taxes, net		162
Interest	553	92
Supplemental disclosure of non-cash transactions:
Purchase of property and equipment by credit	(1)	(32)
Issuance of shares for payment of interest on convertible notes	71
Net change in accrued payroll expenses related to capitalization of technology	$ (259)	$ (41)

XML

Shareholders' Equity (Details) - Employees and directors' stock option [Member] $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2019 USD ($) $ / shares shares
Number of options
Outstanding, Beginning balance | shares	6,474,982
Granted | shares	2,342,500
Exercised | shares	(470,899)
Expired and forfeited | shares	(858,452)
Outstanding, Ending balance | shares	7,488,131
Options vested and expected to vest | shares	7,166,054
Exercisable | shares	4,260,186
Weighted average exercise price
Outstanding, Beginning balance	$ 2.28
Granted	1.94
Exercised	1.58
Expired and forfeited	2.56
Outstanding, Ending balance	2.19
Options vested and expected to vest	2.23
Exercisable options	2.31
Weighted average fair value of options granted during the quarter	$ 0.73
Weighted average remaining contractual term (years)
Outstanding, Beginning balance	3 years 4 months 20 days
Outstanding, Ending balance	3 years 8 months 12 days
Options vested and expected to vest	3 years 7 months 13 days
Exercisable options	2 years 4 months 28 days
Aggregate intrinsic value
Outstanding, Beginning balance | $	$ 4,475
Outstanding, Ending balance | $	184
Options vested and expected to vest | $	178
Exercisable options | $	$ 133

XML

Leases (Details 1) $ in Thousands	Sep. 30, 2019 USD ($)
Leases [Abstract]
2019	$ 474
2020	1,863
2021	1,759
2022	1,206
2023	1,055
Thereafter	4,299
Total undiscounted lease payments	10,656
Less: Interest	1,365
Present value of lease liabilities	$ 9,291

XML

Segment and Geographic Information (Tables)

9 Months Ended

Sep. 30, 2019

Segment Reporting [Abstract]

Schedule of total revenue by solutions offered by geographic area

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
United States	$	4,470	$	4,505	$	13,552	$	11,620
Europe		3,043		3,033		9,190		9,635
Asia Pacific		661		733		1,930		2,199
Israel		1,251		1,214		3,971		2,506
Other		71		77		219		428
	$	9,496	$	9,562	$	28,862	$	26,388

Schedule of net amount of property and equipment

	September 30,		December 31
	2019		2018
	Unaudited
Israel	$	1,367	$	1,217
United States		1,701		1,623
Germany		1,096		1,453
Other		273		315
	$	4,437	$	4,608

XML

Related Parties

9 Months Ended

Sep. 30, 2019

Related Party Transactions [Abstract]

RELATED PARTIES

NOTE 7:- RELATED PARTIES

a. Balances with related parties:

	September 30,		December 31,
	2019		2018
	Unaudited
Prepaid expenses (*)	$	-	$	6

(*) Related to a software license agreement with a related party. See note 7b. for further details.

b. Transactions with related parties:

	Three months ended September 30,				Nine months ended September 30,
	2019		2018		2019		2018
	Unaudited				Unaudited
Software licensing expenses (**)	$	-	$	-	$	-	$	6

(**)  Expenses arising from a software licensing agreement which was executed in March 2017. At the time of execution, the vendor was not a related party. On December 24, 2017, upon completion of the tender offer by WP, the vendor became a related party. The expenses were recorded under research and development expenses net, on the consolidated statements of operations.  The agreement ended March 31, 2019 and has not been renewed.

XML

Leases

9 Months Ended

Sep. 30, 2019

Leases [Abstract]

LEASES

NOTE 3:- LEASES

The Company adopted the new standard as of January 1, 2019, using the modified retrospective approach. The modified retrospective approach provides a method for recording existing leases at adoption and in comparative periods that approximates the results of a full retrospective approach. The Company has elected to utilize the available package of practical expedients permitted under the transition guidance within the new standard which does not require it to reassess the prior conclusions about lease identification, lease classification and initial direct costs.

In addition, the Company has elected the short-term lease exception for leases with a term of 12 months or less. As part of this election it will not recognize right-of-use assets and lease liabilities on the balance sheet for leases with terms less than 12 months.

Some leases include one or more options to extend the lease. The exercise of options to extend the lease is typically at the Company's sole discretion; therefore, the majority of renewals to extend the lease terms are included in our right of use assets and lease liabilities as they are reasonably certain of exercise. The Company regularly evaluates the renewal options, and, when it is reasonably certain of exercise, it will include the renewal period in its lease term. Lease modifications result in remeasurement of the lease liability. 

The right-of-use asset and lease liability are initially measured at the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's incremental borrowing rate based on the information available at the date of adoption in determining the present value of the lease payments.

Some of the real estate leases contain variable lease payments based on an index or rate. Variable lease payments based on an index or rate are initially measured using the index or rate in effect at lease adoption. Additional payments based on the change in an index or rate are recorded as a period expense when incurred.

The Company has various operating leases for office space, vehicles that expire through 2030. Below is a summary of our operating right-of-use assets and operating lease liabilities as of September 30, 2019:

Operating lease right-of-use assets	$	8,974
Operating lease liabilities, current	$	1,298
Operating lease liabilities long-term		7,993
Total operating lease liabilities	$	9,291

The short-term lease liabilities are included within accrued expenses and other short-term liabilities in the consolidated balance sheet.

Minimum lease payments for our right of use assets over the remaining lease periods as of September 30, 2019, are as follows:

Year ended December 31,
2019	$	474
2020		1,863
2021		1,759
2022		1,206
2023		1,055
Thereafter		4,299
Total undiscounted lease payments	$	10,656
Less: Interest		1,365
Present value of lease liabilities		9,291

Premises rent expense was $506 and $536 for the three months ended September 30, 2019 and 2018, respectively and $1,469 and $1,428 for the nine months ended September 30, 2019 and 2018, respectively.

As of September 30, 2019, the Company had an additional operating lease that had not yet commenced in the amount of $3,675. This operating lease will commence in the first quarter of 2020 with a lease term through 2029.

The weighted average remaining lease terms and discount rates for all of operating leases were as follows as of September 30, 2019:

Remaining lease term and discount rate:
Weighted average remaining lease term (years)	2.75
Weighted average discount rate	4.16	%

XML

Shareholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands			9 Months Ended
	Nov. 07, 2019	Dec. 05, 2018	Sep. 30, 2019	Sep. 30, 2018
Shareholders' Equity (Textual)
Options grant/vest, description			The options vest and become exercisable at a rate of 1/16 of the options every three months.
Conversion price, per share	$ 3.73
Gross proceeds	$ 8,019
Interest expense			$ 424
Issuance of new convertible notes [Member]
Shareholders' Equity (Textual)
Aggregate principal amount		$ 10,000
Interest rate		5.75%
Debt instrument, description		(i) 50% cash and (ii) 50% cash or ordinary shares at Cyren's election.
Notes, term		3 years
Conversion price, per share		$ 3.90
Maturity date		Dec. 31, 2021
Semi-annual interest payments, description		In June 2019, the Company paid the first of the semi-annual interest payments totaling, $287, of which $215 was paid in cash and the remaining portion through the issuance of 35,950 shares.
Equity Incentive Plan [Member]
Shareholders' Equity (Textual)
Options grant/vest, description			The per share exercise price for options shall be no less than 100% of the fair market value per ordinary share on the date of grant.
Ordinary shares available for future grant			6,165,694
Options vesting period			4 years
Options expiration term, description			Options granted under the Equity Incentive Plan generally expire after six years from the date of grant.
Annual meeting, description			At the Company's Annual Meeting on July 30, 2019, our shareholders approved an increase in the number of Ordinary Shares reserved for issuance under the 2016 Equity Incentive Plan and its respective Israeli Appendix to a total of 11,200,000.
Restricted Stock Units (RSUs) [Member]
Shareholders' Equity (Textual)
Unrecognized compensation expense			$ 3,217
Recognized over remaining weighted average period			3 years 4 months 17 days
Non-Employee Directors stock option plan [Member]
Shareholders' Equity (Textual)
Options vesting period			4 years
Options expiration term, description			Options granted under the Non-Employee Director Plan generally expire after six years from the date of grant.
Annual meeting, description			At the Company’s Annual Meeting on July 30, 2019, our shareholders approved an increase in the number of Ordinary Shares reserved for issuance under the Non-Employee Director Plan and its respective Israeli Appendix to a total of 1,150,000 Ordinary Shares.
Non-Employee Directors stock option plan [Member] | Non-vested stock options [Member]
Shareholders' Equity (Textual)
Ordinary shares available for future grant			970,214
Unrecognized compensation expense			$ 2,635
Recognized over remaining weighted average period			3 years 1 month 24 days

XML

Related Parties (Details) - USD ($) $ in Thousands		Sep. 30, 2019	Dec. 31, 2018
Related Party Transactions [Abstract]
Prepaid expenses	[1]		$ 6

[1] Related to a software license agreement with a related party. See note 7b. for further details.

XML

Segment and Geographic Information

9 Months Ended

Sep. 30, 2019

Segment Reporting [Abstract]

SEGMENT AND GEOGRAPHIC INFORMATION

NOTE 6:- SEGMENT AND GEOGRAPHIC INFORMATION

Summary information about geographic areas:

ASC 280, "Segment Reporting," establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company manages its business on the basis of one reportable segment and derives revenues from licensing of software and sales of professional services, maintenance and technical support (see note 1 for a brief description of the Company's business). The following is a summary of revenues within geographic areas:

a. The following sets forth total revenue by geographic area based on billing address of the customer:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
United States	$	4,470	$	4,505	$	13,552	$	11,620
Europe		3,043		3,033		9,190		9,635
Asia Pacific		661		733		1,930		2,199
Israel		1,251		1,214		3,971		2,506
Other		71		77		219		428
	$	9,496	$	9,562	$	28,862	$	26,388

b. Major customers:

During the quarter ended September 30, 2019, 20% of the Company's revenues were derived from customer A. During the quarter ended September 30, 2018, 20% of the Company's revenues were derived from customer A.

c. The following sets forth the Company's property and equipment by geographic area:

	September 30,		December 31
	2019		2018
	Unaudited
Israel	$	1,367	$	1,217
United States		1,701		1,623
Germany		1,096		1,453
Other		273		315
	$	4,437	$	4,608

XML

Significant Accounting Policies

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES

a. Interim Financial Statements

The accompanying consolidated balance sheet as of September 30, 2019, the consolidated statements of operations, the consolidated statements of comprehensive loss and the statement of changes in shareholders' equity for the three and nine months ended September 30, 2019 and 2018, as well as the consolidated statements of cash flows for the nine months ended September 30, 2019 and 2018, are unaudited. These unaudited interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP") and applicable rules and regulations of the Securities and Exchange Commission regarding interim financial reporting. In management's opinion, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of the Company's financial position as of September 30, 2019, as well as its results of operations for the three and nine months ended September 30, 2019 and 2018. The results of operations for the three and nine months ended September 30, 2019 are not necessarily indicative of the results to be expected for the year ending December 31, 2019 or for other interim periods or for future years.

b. Over the past several years, the Company has devoted substantially most of its effort to research and development, product development and increasing revenues through additional investments in sales & marketing. The Company generated a loss of $3,530 and $12,679 for the three- and nine-months ending September 30, 2019, negative cash flow of $2,258 from operating activities in the nine months ended September 30, 2019 and has an accumulated deficit of $225,990 as of September 30, 2019. The Company is planning to finance its operations from its existing and future working capital resources and to continue to evaluate additional sources of capital and financing. On September 11, 2019 Cyren announced a rights offering to shareholders of record on September 25 to raise gross proceeds of up to $12,500.  On November 7, 2019 Cyren announced the closing of the offering that raised gross proceeds of $8,019, which will be used toward funding its operations in future quarters.  There is no assurance that additional capital and/or financing will be available to the Company, and even if available, whether it will be on terms acceptable to the Company or in amounts required. Accordingly, the Company's Board previously approved a contingency plan, to be effected if needed, in whole or in part, at its discretion, to allow the Company to continue its operations and meet its cash obligations. The contingency plan consists of cost reduction, which include mainly the following steps: reduction in consultants' expenses, headcount, compensation paid to key management personnel and capital expenditures. The Company and the Board believe that its existing capital resources and other future measures that may be implemented, if so required, will be adequate to satisfy its expected liquidity requirements for at least twelve months from the filing date of this Quarterly Report.

c. Use of estimates:

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company's management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the interim consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. On an ongoing basis, the Company's management evaluates estimates, including those related to fair value and useful lives of intangible assets, fair value of earn-out liabilities, valuation allowance on deferred tax assets, income tax uncertainties, fair values of stock-based awards, other contingent liabilities and estimates used in applying the revenue recognition policy. Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.

d. Significant accounting policies

The accompanying unaudited interim financial statements should be read in conjunction with the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 29, 2019.

There have been no changes in the significant accounting policies from those that were disclosed in the audited consolidated financial statements for the fiscal year ended December 31, 2018 included in the 2018 Form 10-K.

e. Recently issued and adopted pronouncements:

In June 2018, the FASB issued ASU No. 2018-07, "Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting." These amendments expand the scope of Topic 718, Compensation - Stock Compensation (which currently only includes stock-based payments to employees) to include stock-based payments issued to nonemployees for goods or services. Consequently, the accounting for stock-based payments to nonemployees and employees will be substantially aligned. This ASU supersedes Subtopic 505-50, Equity - Equity-Based Payments to Non-Employees. Adoption of this standard had an immaterial impact on the Company's consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, "Leases", on the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard supersedes the lease requirements in Accounting Standards Codification (ASC) Topic 840, "Leases" and requires lessees, to classify leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for in a manner similar to the accounting under existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. The Company adopted ASU 2016-02 as of January 1, 2019, using the modified retrospective approach. For additional information regarding the Company's accounting for leases, please refer to Note 3.

f. New accounting pronouncements not yet adopted:

In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. ASU 2017-04 eliminates step two of the goodwill impairment test and specifies that goodwill impairment should be measured by comparing the fair value of a reporting unit with its carrying amount. Additionally, the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets should be disclosed. ASU 2017-04 is effective for annual or interim goodwill impairment tests performed in fiscal years beginning after December 15, 2019, and early adoption is permitted. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements and footnote disclosures.

In August 2018, the FASB issued ASU No. 2018-15, Customer's Accounting for implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract ("ASU 2018-15"). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The update to the standard is effective for interim and annual periods beginning after December 15, 2019, with early adoption permitted. Entities can choose to adopt the ASU 2018-15 prospectively or retrospectively. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements and footnote disclosures.

XML

Shareholders' Equity (Tables)

9 Months Ended

Sep. 30, 2019

Equity [Abstract]

Schedule of employees and directors' stock option activity

	Number of options			Weighted average exercise price		Weighted average remaining contractual term (years)		Aggregate intrinsic value
Outstanding at December 31, 2018		6,474,982		$	2.28		3.39	$	4,475
Granted		2,342,500			1.94
Exercised		(470,899	)		1.58
Expired and forfeited		(858,452	)		2.56
Outstanding at September 30, 2019		7,488,131		$	2.19		3.70	$	184
Options vested and expected to vest at September 30, 2019		7,166,054		$	2.23		3.62	$	178
Exercisable options at September 30, 2019		4,260,186		$	2.31		2.41	$	133
Weighted average fair value of options granted during the quarter				$	0.73

Schedule of employee and director options outstanding

Outstanding							Exercisable
			Weighted average remaining contractual		Weighted average exercise				Weighted average exercise
	Options		life in		price per		Options		price per
Exercise price per share	outstanding		years		share		exercisable		share
$1.44 - $1.93		1,961,531		4.32	$	1.61		951,031	$	1.57
$2.00 - $2.13		2,402,571		4.30	$	2.06		1,322,571	$	2.03
$2.14 - $2.79		1,634,529		3.23	$	2.48		865,713	$	2.55
$2.90 - $3.07		1,169,000		2.86	$	2.97		812,371	$	2.99
$3.20 - $3.32		320,500		0.79	$	3.32		308,500	$	3.32
		7,488,131		3.70	$	2.23		4,260,186	$	2.31

Schedule of options to non-employees

Issuance date	Options outstanding		Exercise price per share		Options exercisable		Exercisable through
May 14, 2014		3,000	$	3.32		3,000	May-20
February 18, 2015		3,000	$	3.00		3,000	Feb-21
February 10, 2016		40,000	$	1.44		40,000	Feb-22
January 24, 2017		25,000	$	2.00		25,000	Jan-23
		71,000				71,000

Schedule of RSUs activity

	Number of RSUs			Weighted Average Grant Date Fair Value
Awarded and unvested at December 31, 2018		479,000		$	2.47
Granted		1,421,382			2.00
Vested		(119,750	)		2.47
Forfeited		(42,250	)		2.30
Awarded and unvested at September 30, 2019		1,739,382		$	2.09

Schedule of stock-based compensation expense

	Three months ended September 30,				Nine months ended September 30
	2019		2018		2019		2018
	Unaudited				Unaudited
Cost of revenues	$	36	$	48	$	98		124
Research and development		78		105		203		297
Sales and marketing		51		96		148		293
General and administrative		254		109		553		317
	$	419	$	358	$	1,002	$	1,031

XML

Segment and Geographic Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues from external customers	$ 9,496	$ 9,562	$ 28,862	$ 26,388
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues from external customers	4,470	4,505	13,552	11,620
Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues from external customers	3,043	3,033	9,190	9,635
Asia Pacific [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues from external customers	661	733	1,930	2,199
Israel [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues from external customers	1,251	1,214	3,971	2,506
Other [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues from external customers	$ 71	$ 77	$ 219	$ 428

XML

Related Parties (Details 1) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Related Party Transactions [Abstract]
Software licensing expenses	[1]				$ 6

[1] Expenses arising from a software licensing agreement which was executed in March 2017. At the time of execution, the vendor was not a related party. On December 24, 2017, upon completion of the tender offer by WP, the vendor became a related party. The expenses were recorded under research and development expenses net, on the consolidated statements of operations. The agreement ended March 31, 2019 and has not been renewed.

XML

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
CURRENT ASSETS:
Cash and cash equivalents	$ 9,546	$ 17,571
Trade receivables (net of allowances for doubtful accounts of $21 and $20, respectively)	3,499	3,658
Deferred commissions	930	887
Prepaid expenses and other receivables ($- and $6 attributable to related parties)	1,329	778
Total current assets	15,304	22,894
LONG-TERM ASSETS:
Long-term deferred commissions	1,646	1,880
Long-term lease deposits	782	821
Operating lease right-of-use assets	8,974
Severance pay fund	610	503
Property and equipment, net	4,437	4,608
Intangible assets, net	8,667	8,802
Goodwill	19,904	20,519
Total long-term assets	45,020	37,133
Total assets	60,324	60,027
CURRENT LIABILITIES:
Trade payables	1,402	1,668
Employees and payroll accruals	3,690	3,959
Accrued expenses and other liabilities	1,421	910
Operating lease liabilities	1,298
Earn-out consideration		2,926
Deferred revenues	9,270	5,773
Total current liabilities	17,081	15,236
LONG-TERM LIABILITIES:
Deferred revenues	2,944	503
Convertible notes	10,000	10,000
Long-term operating lease liabilities	7,993
Deferred tax liability	912	1,130
Accrued severance pay	778	598
Other liabilities	337	700
Total long-term liabilities	22,964	12,931
SHAREHOLDERS' EQUITY:
Ordinary shares nominal value ILS 0.15 par value - Authorized: 110,000,000 shares at September 30, 2019 (Unaudited) and 75,353,340 shares at December 31, 2018; Issued: 54,683,807 and 54,405,881 shares at September 30, 2019 (Unaudited) and December 31, 2018, respectively; Outstanding: 54,683,807 and 54,057,208 shares at September 30, 2019 (Unaudited) and December 31, 2018, respectively	2,099	2,097
Additional paid-in capital	246,554	245,570
Treasury shares at cost - 0 and 348,673 Ordinary shares at September 30, 2019 (Unaudited) and December 31, 2018, respectively		(998)
Accumulated other comprehensive loss	(2,384)	(1,666)
Accumulated deficit	(225,990)	(213,143)
Total shareholders' equity	20,279	31,860
Total liabilities and shareholders' equity	$ 60,324	$ 60,027

XML

Condensed Consolidated Statements of Changes in Shareholders' Equity (Unaudited) - USD ($) $ in Thousands		Number of outstanding ordinary shares	Additional paid-in capital	Treasury shares	Accumulated other comprehensive income (loss)		Accumulated deficit	Total
Balance beginning at Dec. 31, 2017		$ 2,097	$ 244,609	$ (3,312)	$ (1,195)	[1]	$ (195,098)	$ 47,101
Balance beginning, shares at Dec. 31, 2017		53,375,854
Issuance of treasury shares upon exercise of options and vesting of restricted share units			(451)	2,158		[1]	(431)	1,276
Issuance of treasury shares upon exercise of options and vesting of restricted share units, shares		626,884
Stock-based compensation related to employees, directors and consultants			1,031			[1]		1,031
Other comprehensive loss					(291)	[1]		(291)
Cumulative effect of accounting change						[1]	1,811	1,811
Loss						[1]	(13,842)	(13,842)
Balance ending at Sep. 30, 2018		$ 2,097	245,189	(1,154)	(1,486)	[1]	(207,560)	37,086
Balance ending, shares at Sep. 30, 2018		54,002,738
Balance beginning at Jun. 30, 2018		$ 2,097	245,176	(2,762)	(1,502)	[1]	(202,854)	40,155
Balance beginning, shares at Jun. 30, 2018		53,524,247
Issuance of treasury shares upon exercise of options and vesting of restricted share units			(345)	1,608		[1]	(279)	984
Issuance of treasury shares upon exercise of options and vesting of restricted share units, shares		478,491
Stock-based compensation related to employees, directors and consultants			358			[1]		358
Other comprehensive loss					16	[1]		16
Cumulative effect of accounting change	[1]
Loss						[1]	(4,427)	(4,427)
Balance ending at Sep. 30, 2018		$ 2,097	245,189	(1,154)	(1,486)	[1]	(207,560)	37,086
Balance ending, shares at Sep. 30, 2018		54,002,738
Balance beginning at Dec. 31, 2018		$ 2,097	245,570	(998)	(1,666)	[1]	(213,143)	31,860
Balance beginning, shares at Dec. 31, 2018		54,057,208
Issuance of treasury shares upon exercise of options and vesting of restricted share units			(403)	998		[1]	(168)	427
Issuance of treasury shares upon exercise of options and vesting of restricted share units, shares		348,673
Issuance of ordinary shares upon exercise of options		$ 1	315			[1]		316
Issuance of ordinary shares upon exercise of options, shares		241,976
Payment of interest in shares		$ 1	70			[1]		71
Payment of interest in shares, shares		35,950
Stock-based compensation related to employees, directors and consultants			1,002			[1]		1,002
Other comprehensive loss					(718)	[1]		(718)
Loss						[1]	(12,679)	(12,679)
Balance ending at Sep. 30, 2019		$ 2,099	246,554		(2,384)	[1]	(225,990)	20,279
Balance ending, shares at Sep. 30, 2019		54,683,807
Balance beginning at Jun. 30, 2019		$ 2,098	245,905		(1,762)	[1]	(222,460)	23,781
Balance beginning, shares at Jun. 30, 2019		54,501,307
Issuance of treasury shares upon exercise of options and vesting of restricted share units						[1]
Issuance of treasury shares upon exercise of options and vesting of restricted share units, shares
Issuance of ordinary shares upon exercise of options		$ 1	230			[1]		231
Issuance of ordinary shares upon exercise of options, shares		182,500
Payment of interest in shares						[1]
Payment of interest in shares, shares
Stock-based compensation related to employees, directors and consultants			419			[1]		419
Other comprehensive loss					(622)	[1]		(622)
Loss						[1]	(3,530)	(3,530)
Balance ending at Sep. 30, 2019		$ 2,099	$ 246,554		$ (2,384)	[1]	$ (225,990)	$ 20,279
Balance ending, shares at Sep. 30, 2019		54,683,807

[1] Relates to foreign currency translation adjustments.

XML

Commitments and Contingencies (Details) - USD ($) $ in Thousands	1 Months Ended		9 Months Ended		12 Months Ended
	Feb. 28, 2019	May 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Commitments and Contingencies (Textual)
Research and development			$ 3,699
Payment of earn-out consideration			$ 2,680	$ 604
Royalty rate			The Company is committed to pay royalties at a rate of 3.5% of the program's developed product sales, up to 100% of the amount of grants received plus interest at annual LIBOR rate.
Net of royalties paid or accrued			$ 2,717		$ 2,734
Settle of earn-out consideration	$ 2,680
License fees			$ 3,150
Claims settlement amount	$ 256
Majority Shareholder [Member]
Commitments and Contingencies (Textual)
Payment of earn-out consideration		$ 604

XML

Leases (Details) $ in Thousands	Sep. 30, 2019 USD ($)
Leases [Abstract]
Operating lease right-of-use assets	$ 8,974
Operating lease liabilities, current	1,298
Operating lease liabilities long-term	7,993
Total operating lease liabilities	$ 9,291

XML

Shareholders' Equity (Details 4) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	$ 419	$ 358	$ 1,002	$ 1,031
Cost of revenues [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	36	48	98	124
Research and development [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	78	105	203	297
Sales and marketing [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	51	96	148	293
General and administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	$ 254	$ 109	$ 553	$ 317

XML

Segment and Geographic Information (Details Textual) - Segment	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Segment and Geographic Information (Textual)
Number of reportable segments	1
Segment reporting, major customer's description	20% of the Company's revenues were derived from customer A.	20% of the Company's revenues were derived from customer A.

XML

Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Interim Financial Statements

a. Interim Financial Statements

The accompanying consolidated balance sheet as of September 30, 2019, the consolidated statements of operations, the consolidated statements of comprehensive loss and the statement of changes in shareholders' equity for the three and nine months ended September 30, 2019 and 2018, as well as the consolidated statements of cash flows for the nine months ended September 30, 2019 and 2018, are unaudited. These unaudited interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP") and applicable rules and regulations of the Securities and Exchange Commission regarding interim financial reporting. In management's opinion, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of the Company's financial position as of September 30, 2019, as well as its results of operations for the three and nine months ended September 30, 2019 and 2018. The results of operations for the three and nine months ended September 30, 2019 are not necessarily indicative of the results to be expected for the year ending December 31, 2019 or for other interim periods or for future years.

b. Over the past several years, the Company has devoted substantially most of its effort to research and development, product development and increasing revenues through additional investments in sales & marketing. The Company generated a loss of $3,530 and $12,679 for the three- and nine-months ending September 30, 2019, negative cash flow of $2,258 from operating activities in the nine months ended September 30, 2019 and has an accumulated deficit of $225,990 as of September 30, 2019. The Company is planning to finance its operations from its existing and future working capital resources and to continue to evaluate additional sources of capital and financing. On September 11, 2019 Cyren announced a rights offering to shareholders of record on September 25 to raise gross proceeds of up to $12,500.  On November 7, 2019 Cyren announced the closing of the offering that raised gross proceeds of $8,019, which will be used toward funding its operations in future quarters.  There is no assurance that additional capital and/or financing will be available to the Company, and even if available, whether it will be on terms acceptable to the Company or in amounts required. Accordingly, the Company's Board previously approved a contingency plan, to be effected if needed, in whole or in part, at its discretion, to allow the Company to continue its operations and meet its cash obligations. The contingency plan consists of cost reduction, which include mainly the following steps: reduction in consultants' expenses, headcount, compensation paid to key management personnel and capital expenditures. The Company and the Board believe that its existing capital resources and other future measures that may be implemented, if so required, will be adequate to satisfy its expected liquidity requirements for at least twelve months from the filing date of this Quarterly Report.

Use of estimates

c. Use of estimates:

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company's management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the interim consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. On an ongoing basis, the Company's management evaluates estimates, including those related to fair value and useful lives of intangible assets, fair value of earn-out liabilities, valuation allowance on deferred tax assets, income tax uncertainties, fair values of stock-based awards, other contingent liabilities and estimates used in applying the revenue recognition policy. Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.

Significant accounting policies

d. Significant accounting policies

The accompanying unaudited interim financial statements should be read in conjunction with the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 29, 2019.

There have been no changes in the significant accounting policies from those that were disclosed in the audited consolidated financial statements for the fiscal year ended December 31, 2018 included in the 2018 Form 10-K.

Recently issued and adopted pronouncements

e. Recently issued and adopted pronouncements:

In June 2018, the FASB issued ASU No. 2018-07, "Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting." These amendments expand the scope of Topic 718, Compensation - Stock Compensation (which currently only includes stock-based payments to employees) to include stock-based payments issued to nonemployees for goods or services. Consequently, the accounting for stock-based payments to nonemployees and employees will be substantially aligned. This ASU supersedes Subtopic 505-50, Equity - Equity-Based Payments to Non-Employees. Adoption of this standard had an immaterial impact on the Company's consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, "Leases", on the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard supersedes the lease requirements in Accounting Standards Codification (ASC) Topic 840, "Leases" and requires lessees, to classify leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for in a manner similar to the accounting under existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. The Company adopted ASU 2016-02 as of January 1, 2019, using the modified retrospective approach. For additional information regarding the Company's accounting for leases, please refer to Note 3.

New accounting pronouncements not yet adopted

f. New accounting pronouncements not yet adopted:

In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. ASU 2017-04 eliminates step two of the goodwill impairment test and specifies that goodwill impairment should be measured by comparing the fair value of a reporting unit with its carrying amount. Additionally, the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets should be disclosed. ASU 2017-04 is effective for annual or interim goodwill impairment tests performed in fiscal years beginning after December 15, 2019, and early adoption is permitted. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements and footnote disclosures.

In August 2018, the FASB issued ASU No. 2018-15, Customer's Accounting for implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract ("ASU 2018-15"). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The update to the standard is effective for interim and annual periods beginning after December 15, 2019, with early adoption permitted. Entities can choose to adopt the ASU 2018-15 prospectively or retrospectively. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements and footnote disclosures.

XML

Commitments and Contingencies

9 Months Ended

Sep. 30, 2019

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 4:- COMMITMENTS AND CONTINGENCIES

a. Cyren Ltd., which was incorporated in Israel, partially financed its research and development expenditures under programs sponsored by the Israel Innovation Authority ("IIA") for the support of certain research and development activities conducted in Israel.

In connection with specific research and development, the Company received $3,699 of participation payments from the IIA through September 30, 2019. In return for the IIA's participation in this program, the Company is committed to pay royalties at a rate of 3.5% of the program's developed product sales, up to 100% of the amount of grants received plus interest at annual LIBOR rate. The Company's total commitment for royalties payable with respect to future sales, based on IIA participations received, net of royalties paid or accrued, totaled $2,717 and $2,734 as of September 30, 2019 and December 31, 2018 respectively.

b. Litigations:

i.  Between 2014 and 2015 the Company entered into arbitral proceedings with the former shareholders of eleven regarding an escrow account and the earn-out consideration related to the purchase agreement of former eleven. With respect to these claims, on March 9, 2017, the arbitrational panel provided their ruling in which it accepted the claims submitted by the former eleven shareholders with respect to the escrow amount and the 2013 earn-out liability. The arbitrational panel also ruled that Cyren pay legal expenses and interest on the claimed amounts, which were reflected in the year ending December 31, 2016 on the Company's balance sheet and in the consolidated statements of operations under adjustment to earn-out consideration.   The escrow account has been released to the former shareholders. The arbitrational award related to the 2013 earn-out consideration was declared enforceable by the applicable courts in Germany. Accordingly, on May 30, 2018, the Company paid the portion of the earn-out consideration in the amount of $604 that was declared enforceable by the German district court. The Company did not pay the remainder of the earn-out consideration, including accrued legal and interest, which appear on the Company's consolidated balance sheets as of December 31, 2018, and has filed an appeal to the German Federal Supreme Court challenging the enforceability of the remaining amounts.   In February 2019, the parties signed a settlement agreement to resolve all pending claims, and on February 28, 2019 the Company paid $2,680 to settle the earn-out consideration in full. The total amount paid to resolve all claims was $256 less than the accrued liability, which generated "other income" as previously reflected in the consolidated statement of operations for the period ending March 31, 2019.

ii. On September 28, 2017 a former vendor filed a Statement of Claim in the Tel Aviv District Court (the "SOC"). According to the vendor's SOC, the Company entered into an agreement with the vendor for receipt of services, based on a database developed by the vendor. In September 2015, the Company terminated the agreement with the vendor, effective as of December 31, 2015. The vendor claims that the Company continues to make use of the vendor's database post termination, thus breaching the agreement, infringing on the vendor's rights and commercial secrets, and being unjustly enriched.

The vendor is claiming license fees of approximately $3,150 and an injunction relief ordering the Company and/or its customers to delete any remaining data and to cease from utilizing such data.

The Company denies all claims and filed a Statement of Defense on November 15, 2017. Pretrial was scheduled for May 15, 2018. In accordance with the court's recommendation from November 28, 2017, the parties agreed to examine a non-binding mediation process and appointed a mediator. The parties agreed to conduct a third-party audit of the Company's databases in the scope of the mediation and the audit is currently being conducted. At this early stage, the Company is unable to make any estimations as to the outcome of this litigation.

In September 2018 and January 2019, the same vendor filed a lawsuit against two of the Company's customers in the United States. The vendor alleges that the clients misappropriated the vendor's trade secrets and is seeking injunctive relief and monetary damages in an amount to be determined. Both customers contended that the allegations relate to the services they received from the Company, and the Company agreed to indemnify both clients against these claims. As such, the Company has taken over the representation in these lawsuits. On September 30, 2019, the court dismissed one of the lawsuits in its entirety for lack of personal jurisdiction and, in the second lawsuit, dismissed part of the claims with prejudice but granted the vendor the right to amend its other claims. On October 31, 2019, the vendor filed an amended complaint. At this early stage, the Company is unable to make any estimations as to the outcome of these litigations.

XML

Shareholders' Equity (Details 1)	9 Months Ended
	Sep. 30, 2019 $ / shares shares
Schedule of employee and director options outstanding
Outstanding, Options outstanding | shares	7,488,131
Outstanding, Weighted average remaining contractual life in years	3 years 8 months 12 days
Outstanding, Weighted average exercise price per share	$ 2.23
Exercisable, Options exercisable | shares	4,260,186
Exercisable, Weighted average exercise price per share	$ 2.31
$1.44 - $1.93 [Member]
Schedule of employee and director options outstanding
Outstanding, Exercise price per share, lower limit	1.44
Outstanding, Exercise price per share, upper limit	$ 1.93
Outstanding, Options outstanding | shares	1,961,531
Outstanding, Weighted average remaining contractual life in years	4 years 3 months 26 days
Outstanding, Weighted average exercise price per share	$ 1.61
Exercisable, Options exercisable | shares	951,031
Exercisable, Weighted average exercise price per share	$ 1.57
$2.00 - $2.13 [Member]
Schedule of employee and director options outstanding
Outstanding, Exercise price per share, lower limit	2.00
Outstanding, Exercise price per share, upper limit	$ 2.13
Outstanding, Options outstanding | shares	2,402,571
Outstanding, Weighted average remaining contractual life in years	4 years 3 months 19 days
Outstanding, Weighted average exercise price per share	$ 2.06
Exercisable, Options exercisable | shares	1,322,571
Exercisable, Weighted average exercise price per share	$ 2.03
$2.14 - $2.79 [Member]
Schedule of employee and director options outstanding
Outstanding, Exercise price per share, lower limit	2.14
Outstanding, Exercise price per share, upper limit	$ 2.79
Outstanding, Options outstanding | shares	1,634,529
Outstanding, Weighted average remaining contractual life in years	3 years 2 months 23 days
Outstanding, Weighted average exercise price per share	$ 2.48
Exercisable, Options exercisable | shares	865,713
Exercisable, Weighted average exercise price per share	$ 2.55
$2.90 - $3.07 [Member]
Schedule of employee and director options outstanding
Outstanding, Exercise price per share, lower limit	2.90
Outstanding, Exercise price per share, upper limit	$ 3.07
Outstanding, Options outstanding | shares	1,169,000
Outstanding, Weighted average remaining contractual life in years	2 years 10 months 10 days
Outstanding, Weighted average exercise price per share	$ 2.97
Exercisable, Options exercisable | shares	812,371
Exercisable, Weighted average exercise price per share	$ 2.99
$3.20 - $3.32 [Member]
Schedule of employee and director options outstanding
Outstanding, Exercise price per share, lower limit	3.20
Outstanding, Exercise price per share, upper limit	$ 3.32
Outstanding, Options outstanding | shares	320,500
Outstanding, Weighted average remaining contractual life in years	9 months 14 days
Outstanding, Weighted average exercise price per share	$ 3.32
Exercisable, Options exercisable | shares	308,500
Exercisable, Weighted average exercise price per share	$ 3.32

XML

Leases (Details 2)	Sep. 30, 2019
Remaining lease term and discount rate:
Weighted average remaining lease term (years)	2 years 9 months
Weighted average discount rate	4.16%

XML

Related Parties (Tables)

9 Months Ended

Sep. 30, 2019

Related Party Transactions [Abstract]

Schedule of balances with related parties

	September 30,		December 31,
	2019		2018
	Unaudited
Prepaid expenses (*)	$	-	$	6

(*) Related to a software license agreement with a related party. See note 7b. for further details.

Schedule of transactions with related parties

	Three months ended September 30,				Nine months ended September 30,
	2019		2018		2019		2018
	Unaudited				Unaudited
Software licensing expenses (**)	$	-	$	-	$	-	$	6

(**)  Expenses arising from a software licensing agreement which was executed in March 2017. At the time of execution, the vendor was not a related party. On December 24, 2017, upon completion of the tender offer by WP, the vendor became a related party. The expenses were recorded under research and development expenses net, on the consolidated statements of operations.  The agreement ended March 31, 2019 and has not been renewed.

XML

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Statement [Abstract]
Revenues		$ 9,496	$ 9,562	$ 28,862	$ 26,388
Cost of revenues		3,712	3,670	11,501	10,684
Gross profit		5,784	5,892	17,361	15,704
Operating expenses:
Research and development, net	[1]	3,516	4,336	11,990	11,355
Sales and marketing		3,027	3,931	10,473	12,133
General and administrative		2,484	2,166	7,314	6,151
Total operating expenses		9,027	10,433	29,777	29,639
Operating loss		(3,243)	(4,541)	(12,416)	(13,935)
Other income (expense), net		(3)		262	(17)
Financial income (expense), net		(321)	7	(642)	(91)
Loss before taxes on income		(3,567)	(4,534)	(12,796)	(14,043)
Tax benefit		37	107	117	201
Loss		$ (3,530)	$ (4,427)	$ (12,679)	$ (13,842)
Basic and diluted loss per share		$ (0.06)	$ (0.08)	$ (0.23)	$ (0.26)
Weighted average number of shares used in computing basic and diluted loss per share		54,554	53,679	54,389	53,503

[1] Transactions with related parties are included in the line item above (refer to Footnote 7, Related Parties, of the Notes to Consolidated Financial Statements for additional information).

XML

Condensed Consolidated Statements of Cash Flows (Reconciliation of Cash, Cash Equivalents and Restricted Cash) - USD ($) $ in Thousands	Sep. 30, 2019	Sep. 30, 2018
Reconciliation of cash, cash equivalents and restricted cash as shown in the condensed consolidated statements of cash flow:
Cash and cash equivalents	$ 9,546	$ 13,527
Restricted cash included in long-term restricted lease deposits	571	606
Total cash, cash equivalents and restricted cash	$ 10,117	$ 14,133

XML

Leases (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Leases (Textual)
Leases, description			The Company has various operating leases for office space, vehicles that expire through 2030.
Operating lease term, description			The Company had an additional operating lease that had not yet commenced in the amount of $3,675. This operating lease will commence in the first quarter of 2020 with a lease term through 2029.
Premises rent expense	$ 506	$ 536	$ 1,469	$ 1,428

XML

Significant Accounting Policies (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Significant Accounting Policies (Textual)
Loss		$ (3,530)	$ (4,427)	$ (12,679)	$ (13,842)
Net cash used in operating activities				(2,258)	$ (5,895)
Accumulated deficit	$ (225,990)	$ (225,990)		$ (225,990)		$ (213,143)
Offering, description	Cyren announced a rights offering to shareholders of record on September 25 to raise gross proceeds of up to $12,500.			On November 7, 2019 Cyren announced the closing of the offering that raised gross proceeds of $8,019, which will be used toward funding its operations in future quarters.

XML

Shareholders' Equity (Details 2) - Options to non-employees [Member]	9 Months Ended
	Sep. 30, 2019 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding	71,000
Options exercisable	71,000
May 14, 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance date	May 14, 2014
Options outstanding	3,000
Exercise price per share | $ / shares	$ 3.32
Options exercisable	3,000
Exercisable through	May-20
February 18, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance date	Feb. 18, 2015
Options outstanding	3,000
Exercise price per share | $ / shares	$ 3.00
Options exercisable	3,000
Exercisable through	Feb - 21
February 10, 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance date	Feb. 10, 2016
Options outstanding	40,000
Exercise price per share | $ / shares	$ 1.44
Options exercisable	40,000
Exercisable through	Feb-22
January 24, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance date	Jan. 24, 2017
Options outstanding	25,000
Exercise price per share | $ / shares	$ 2.00
Options exercisable	25,000
Exercisable through	Jan-23

XML

General

9 Months Ended

Sep. 30, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

GENERAL

NOTE 1:- GENERAL

Cyren Ltd. (henceforth "Cyren") was incorporated under the laws of the State of Israel on February 10, 1991 and its legal form is a company limited by shares. Cyren listed its shares to the public on July 15, 1999 under the name Commtouch Software Ltd. and changed its legal name to Cyren Ltd. in January 2014. Cyren and its subsidiaries, unless otherwise indicated will be referred to in these consolidated financial statements as the "Company".

The Company is engaged in developing and marketing information security solutions for protecting web, email and mobile transactions. The Company sells its cloud-based solutions worldwide, in both embedded and Security-as-a-Service models, to Original Equipment Manufacturers ("OEMs"), service providers and enterprises. The Company operates in one reportable segment, which constitutes its reporting unit.

XML

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 07, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	CYREN Ltd.
Entity Central Index Key	0001084577
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		59,319,391
Entity File Number	000-26495
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	L3

XML

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Statement of Comprehensive Income [Abstract]
Loss	$ (3,530)	$ (4,427)	$ (12,679)	$ (13,842)
Other comprehensive income (loss):
Foreign currency translation adjustments	(622)	16	(718)	(291)
Comprehensive loss	$ (4,152)	$ (4,411)	$ (13,397)	$ (14,133)

XML

Shareholders' Equity (Details 3) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Sep. 30, 2019 $ / shares shares
Number of RSUs
Awarded and unvested at December 31, 2018 | shares	479,000
Granted | shares	1,421,382
Vested | shares	(119,750)
Forfeited | shares	(42,250)
Awarded and unvested at September 30, 2019 | shares	1,739,382
Weighted Average Grant Date Fair Value
Awarded and unvested at December 31, 2018 | $ / shares	$ 2.47
Granted | $ / shares	2.00
Vested | $ / shares	2.47
Forfeited | $ / shares	2.30
Awarded and unvested at September 30, 2019 | $ / shares	$ 2.09

XML

Segment and Geographic Information (Details 1) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Revenues from External Customers and Long-Lived Assets [Line Items]
Net amount of property and equipment	$ 4,437	$ 4,608
Israel [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net amount of property and equipment	1,367	1,217
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net amount of property and equipment	1,701	1,623
Germany [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net amount of property and equipment	1,096	1,453
Other [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net amount of property and equipment	$ 273	$ 315

XML

Leases (Tables)

9 Months Ended

Sep. 30, 2019

Leases [Abstract]

Schedule of operating right-of-use assets and operating lease liabilities

Operating lease right-of-use assets	$	8,974
Operating lease liabilities, current	$	1,298
Operating lease liabilities long-term		7,993
Total operating lease liabilities	$	9,291

Schedule of future minimum lease payments

Year ended December 31,
2019	$	474
2020		1,863
2021		1,759
2022		1,206
2023		1,055
Thereafter		4,299
Total undiscounted lease payments	$	10,656
Less: Interest		1,365
Present value of lease liabilities		9,291

Schedule of weighted average remaining lease terms and discount rates for all of operating leases

Remaining lease term and discount rate:
Weighted average remaining lease term (years)	2.75
Weighted average discount rate	4.16	%

XML

Shareholders' Equity

9 Months Ended

Sep. 30, 2019

Equity [Abstract]

SHAREHOLDERS' EQUITY

NOTE 5:- ShareHOLDERS' EQUITY

a. General:

Ordinary shares confer upon their holders the right to receive notice to participate and vote in general shareholder meetings of the Company and to receive dividends, if declared.

b. Issuance of new convertible notes:

On December 5, 2018 the Company issued $10,000 aggregate principal amount of convertible notes in a private offering. The notes are unsecured, unsubordinated obligations of Cyren and carry a 5.75% interest rate, payable semi-annually in (i) 50% cash and (ii) 50% cash or ordinary shares at Cyren's election. The notes have a 3-year term and are expected to mature in December 2021, unless converted in accordance with their terms prior to maturity. The notes were issued with a conversion price of $3.90 per share which was subject to adjustment using a weighted average ratchet mechanism based on the size and price of future equity offerings and the total shares outstanding. On November 7, 2019 Cyren announced the closing of a rights offering that raised gross proceeds of $8,019. As a result of this offering, the conversion price of the convertible notes was adjusted to $3.73. In addition, the notes would be subject to immediate conversion upon any change in control in the Company (or subject to repayment if the price in the change in control transaction is less than the conversion price). The Company incurred interest expense for the nine months ended September 30, 2019 of $424. In June 2019, the Company paid the first of the semi-annual interest payments totaling, $287, of which $215 was paid in cash and the remaining portion through the issuance of 35,950 shares.

c. Equity Incentive Plan:

In 1996, the Company adopted the 1996 CSI Share Option Plan for granting options to its U.S. employees and consultants to purchase ordinary shares of the Company, which was replaced in 2006 by the 2006 U.S. Share Option Plan. Until 1999, the Company issued options to purchase ordinary shares to its Israeli employees pursuant to individual agreements. In 1999, the Company approved the 1999 Section 3(i) stock option plan for its Israeli employees and consultants, (which was amended in 2003 and renamed the "Amended and Restated Israeli Share Option Plan"). On December 22, 2016, the Company's shareholders approved a new stock option plan - the 2016 Equity Incentive Plan (the "Equity Incentive Plan"). This plan, along with its respective Israeli appendix, has replaced all existing employee and consultants stock option plans which have terminated.

The Equity Incentive Plan allows for the issuance of Restricted Share Units ("RSUs"), as well as options. The options and RSUs generally vest over a period of four years. Options granted under the Equity Incentive Plan generally expire after six years from the date of grant. Options and RSUs cease vesting upon termination of the optionee's employment or other relationship with the Company. The per share exercise price for options shall be no less than 100% of the fair market value per ordinary share on the date of grant. Any options and RSUs that are canceled or not exercised within the option term become available for future grant.

As of September 30, 2019, an aggregate of 6,165,694 ordinary shares of the Company are available for future grant under the Equity Incentive Plan. At the Company's Annual Meeting on July 30, 2019, our shareholders approved an increase in the number of Ordinary Shares reserved for issuance under the 2016 Equity Incentive Plan and its respective Israeli Appendix to a total of 11,200,000.

d. Non-Employee Directors stock option plan:

In 1999, the Company adopted the 1999 Directors Share Option Plan, and in 2008 shareholders approved an extension of the term of this plan through July 13, 2019. On December 15, 2006, the plan was extended through 2016. On December 22, 2016, the Company's shareholders approved a new stock option plan - the 2016 Non-Employee Director Equity Incentive Plan (the "Non-Employee Director Plan"). This plan, along with its respective Israeli appendix, has replaced all existing Directors stock option plans which have terminated.

The Non-Employee Director Plan allows for the issuance of Restricted Share Units ("RSUs"), as well as options. Each option and RSU granted under the Non-Employee Plan generally vests over a period of four years. Each option has an exercise price equal to the fair market value of the ordinary shares on the grant date of such option. Options granted under the Non-Employee Director Plan generally expire after six years from the date of grant. Options and RSUs cease vesting upon termination of the relationship with the Company.

As of September 30, 2019, an aggregate of 970,214 ordinary shares of the Company are still available for future grant to non-employee directors. At the Company's Annual Meeting on July 30, 2019, our shareholders approved an increase in the number of Ordinary Shares reserved for issuance under the Non-Employee Director Plan and its respective Israeli Appendix to a total of 1,150,000 Ordinary Shares.

e. A summary of the Company's employees and directors' stock option activity under the plans is as follows:

	Number of options			Weighted average exercise price		Weighted average remaining contractual term (years)		Aggregate intrinsic value
Outstanding at December 31, 2018		6,474,982		$	2.28		3.39	$	4,475
Granted		2,342,500			1.94
Exercised		(470,899	)		1.58
Expired and forfeited		(858,452	)		2.56
Outstanding at September 30, 2019		7,488,131		$	2.19		3.70	$	184
Options vested and expected to vest at September 30, 2019		7,166,054		$	2.23		3.62	$	178
Exercisable options at September 30, 2019		4,260,186		$	2.31		2.41	$	133
Weighted average fair value of options granted during the quarter				$	0.73

As of September 30, 2019, the Company had $2,635 of unrecognized compensation expense related to non-vested stock options granted to employees and directors, expected to be recognized over a remaining weighted average period of 3.15 years.

f. The employee and director options outstanding as of September 30, 2019, have been separated into ranges of exercise prices, as follows:

Outstanding							Exercisable
			Weighted average remaining contractual		Weighted average exercise				Weighted average exercise
	Options		life in		price per		Options		price per
Exercise price per share	outstanding		years		share		exercisable		share
$1.44 - $1.93		1,961,531		4.32	$	1.61		951,031	$	1.57
$2.00 - $2.13		2,402,571		4.30	$	2.06		1,322,571	$	2.03
$2.14 - $2.79		1,634,529		3.23	$	2.48		865,713	$	2.55
$2.90 - $3.07		1,169,000		2.86	$	2.97		812,371	$	2.99
$3.20 - $3.32		320,500		0.79	$	3.32		308,500	$	3.32
		7,488,131		3.70	$	2.23		4,260,186	$	2.31

g Options to non-employees:

Issuance date	Options outstanding		Exercise price per share		Options exercisable		Exercisable through
May 14, 2014		3,000	$	3.32		3,000	May-20
February 18, 2015		3,000	$	3.00		3,000	Feb-21
February 10, 2016		40,000	$	1.44		40,000	Feb-22
January 24, 2017		25,000	$	2.00		25,000	Jan-23
		71,000				71,000

The options vest and become exercisable at a rate of 1/16 of the options every three months.

h. A summary of the Company's RSUs activity for employees, directors and non-employees under the plans is as follows:

	Number of RSUs			Weighted Average Grant Date Fair Value
Awarded and unvested at December 31, 2018		479,000		$	2.47
Granted		1,421,382			2.00
Vested		(119,750	)		2.47
Forfeited		(42,250	)		2.30
Awarded and unvested at September 30, 2019		1,739,382		$	2.09

As of September 30, 2019, the Company had approximately $3,217 of unrecognized compensation expense related to RSUs, expected to be recognized over a weighted average period of 3.38 years.

i. The total stock-based compensation expense related to all of the Company's equity-based awards, recognized for the three and nine months ended September 30, 2019 and 2018 was as follows:

	Three months ended September 30,				Nine months ended September 30
	2019		2018		2019		2018
	Unaudited				Unaudited
Cost of revenues	$	36	$	48	$	98		124
Research and development		78		105		203		297
Sales and marketing		51		96		148		293
General and administrative		254		109		553		317
	$	419	$	358	$	1,002	$	1,031